#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Structural and Functional Neuroimaging of Polygenic Risk for Schizophrenia: A Recall-by-Genotype–Based Approach Abstract Risk profile scores (RPS) derived from genome-wide association studies (GWAS) explain a considerable amount of susceptibility for schizophrenia (SCZ).
1-1	0-10	Structural	_
1-2	11-14	and	_
1-3	15-25	Functional	_
1-4	26-38	Neuroimaging	_
1-5	39-41	of	_
1-6	42-51	Polygenic	_
1-7	52-56	Risk	_
1-8	57-60	for	_
1-9	61-74	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-10	75-76	:	_
1-11	77-78	A	_
1-12	79-103	Recall-by-Genotype–Based	_
1-13	104-112	Approach	_
1-14	113-121	Abstract	_
1-15	122-126	Risk	_
1-16	127-134	profile	_
1-17	135-141	scores	_
1-18	142-143	(	_
1-19	144-147	RPS	_
1-20	148-149	)	_
1-21	150-157	derived	_
1-22	158-162	from	_
1-23	163-174	genome-wide	_
1-24	175-186	association	_
1-25	187-194	studies	_
1-26	195-196	(	_
1-27	197-201	GWAS	_
1-28	202-203	)	_
1-29	204-211	explain	_
1-30	212-213	a	_
1-31	214-226	considerable	_
1-32	227-233	amount	_
1-33	234-236	of	_
1-34	237-251	susceptibility	_
1-35	252-255	for	_
1-36	256-269	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-37	270-271	(	_
1-38	272-275	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-39	276-277	)	_
1-40	278-279	.	_

Text=However, little is known about how common genetic risk factors for SCZ influence the structure and function of the human brain, largely due to the constraints of imaging sample sizes.
2-1	280-287	However	_
2-2	288-289	,	_
2-3	290-296	little	_
2-4	297-299	is	_
2-5	300-305	known	_
2-6	306-311	about	_
2-7	312-315	how	_
2-8	316-322	common	_
2-9	323-330	genetic	_
2-10	331-335	risk	_
2-11	336-343	factors	_
2-12	344-347	for	_
2-13	348-351	SCZ	_
2-14	352-361	influence	_
2-15	362-365	the	_
2-16	366-375	structure	_
2-17	376-379	and	_
2-18	380-388	function	_
2-19	389-391	of	_
2-20	392-395	the	_
2-21	396-401	human	_
2-22	402-407	brain	_
2-23	408-409	,	_
2-24	410-417	largely	_
2-25	418-421	due	_
2-26	422-424	to	_
2-27	425-428	the	_
2-28	429-440	constraints	_
2-29	441-443	of	_
2-30	444-451	imaging	_
2-31	452-458	sample	_
2-32	459-464	sizes	_
2-33	465-466	.	_

Text=In the current study, we use a novel recall-by-genotype (RbG) methodological approach, where we sample young adults from a population cohort (Avon Longitudinal Study of Parents and Children: N genotyped = 8365) based on their SCZ-RPS.
3-1	467-469	In	_
3-2	470-473	the	_
3-3	474-481	current	_
3-4	482-487	study	_
3-5	488-489	,	_
3-6	490-492	we	_
3-7	493-496	use	_
3-8	497-498	a	_
3-9	499-504	novel	_
3-10	505-523	recall-by-genotype	_
3-11	524-525	(	_
3-12	526-529	RbG	_
3-13	530-531	)	_
3-14	532-546	methodological	_
3-15	547-555	approach	_
3-16	556-557	,	_
3-17	558-563	where	_
3-18	564-566	we	_
3-19	567-573	sample	_
3-20	574-579	young	_
3-21	580-586	adults	_
3-22	587-591	from	_
3-23	592-593	a	_
3-24	594-604	population	_
3-25	605-611	cohort	_
3-26	612-613	(	_
3-27	614-618	Avon	_
3-28	619-631	Longitudinal	_
3-29	632-637	Study	_
3-30	638-640	of	_
3-31	641-648	Parents	_
3-32	649-652	and	_
3-33	653-661	Children	_
3-34	662-663	:	_
3-35	664-665	N	_
3-36	666-675	genotyped	_
3-37	676-677	=	_
3-38	678-682	8365	_
3-39	683-684	)	_
3-40	685-690	based	_
3-41	691-693	on	_
3-42	694-699	their	_
3-43	700-707	SCZ-RPS	_
3-44	708-709	.	_

Text=We compared 197 healthy individuals at extremes of low (N = 99) or high (N = 98) SCZ-RPS with behavioral tests, and structural and functional magnetic resonance imaging (fMRI).
4-1	710-712	We	_
4-2	713-721	compared	_
4-3	722-725	197	_
4-4	726-733	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-5	734-745	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-6	746-748	at	_
4-7	749-757	extremes	_
4-8	758-760	of	_
4-9	761-764	low	_
4-10	765-766	(	_
4-11	767-768	N	_
4-12	769-770	=	_
4-13	771-773	99	_
4-14	774-775	)	_
4-15	776-778	or	_
4-16	779-783	high	_
4-17	784-785	(	_
4-18	786-787	N	_
4-19	788-789	=	_
4-20	790-792	98	_
4-21	793-794	)	_
4-22	795-802	SCZ-RPS	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-23	803-807	with	_
4-24	808-818	behavioral	_
4-25	819-824	tests	_
4-26	825-826	,	_
4-27	827-830	and	_
4-28	831-841	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
4-29	842-845	and	_
4-30	846-856	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-31	857-865	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-32	866-875	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-33	876-883	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-34	884-885	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-35	886-890	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-36	891-892	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-37	893-894	.	_

Text=We first provide methodological details that will inform the design of future RbG studies for common SCZ genetic risk.
5-1	895-897	We	_
5-2	898-903	first	_
5-3	904-911	provide	_
5-4	912-926	methodological	_
5-5	927-934	details	_
5-6	935-939	that	_
5-7	940-944	will	_
5-8	945-951	inform	_
5-9	952-955	the	_
5-10	956-962	design	_
5-11	963-965	of	_
5-12	966-972	future	_
5-13	973-976	RbG	_
5-14	977-984	studies	_
5-15	985-988	for	_
5-16	989-995	common	_
5-17	996-999	SCZ	_
5-18	1000-1007	genetic	_
5-19	1008-1012	risk	_
5-20	1013-1014	.	_

Text=We further provide an between group analysis of the RbG individuals (low vs high SCZ-RPS) who underwent structural neuroimaging data (T1—weighted scans) and fMRI data during a reversal learning task.
6-1	1015-1017	We	_
6-2	1018-1025	further	_
6-3	1026-1033	provide	_
6-4	1034-1036	an	_
6-5	1037-1044	between	_
6-6	1045-1050	group	_
6-7	1051-1059	analysis	_
6-8	1060-1062	of	_
6-9	1063-1066	the	_
6-10	1067-1070	RbG	_
6-11	1071-1082	individuals	_
6-12	1083-1084	(	_
6-13	1085-1088	low	_
6-14	1089-1091	vs	_
6-15	1092-1096	high	_
6-16	1097-1104	SCZ-RPS	_
6-17	1105-1106	)	_
6-18	1107-1110	who	_
6-19	1111-1120	underwent	_
6-20	1121-1131	structural	_
6-21	1132-1144	neuroimaging	_
6-22	1145-1149	data	_
6-23	1150-1151	(	_
6-24	1152-1163	T1—weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
6-25	1164-1169	scans	_
6-26	1170-1171	)	_
6-27	1172-1175	and	_
6-28	1176-1180	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
6-29	1181-1185	data	_
6-30	1186-1192	during	_
6-31	1193-1194	a	_
6-32	1195-1203	reversal	_
6-33	1204-1212	learning	_
6-34	1213-1217	task	_
6-35	1218-1219	.	_

Text=While we found little evidence for morphometric differences between the low and high SCZ-RPS groups, we observed an impact of SCZ-RPS on blood oxygen level-dependent (BOLD) signal during reward processing in the ventral striatum (PFWE-VS-CORRECTED = .037), a previously investigated broader reward-related network (PFWE-ROIS-CORRECTED = .008), and across the whole brain (PFWE-WHOLE-BRAIN-CORRECTED = .013).
7-1	1220-1225	While	_
7-2	1226-1228	we	_
7-3	1229-1234	found	_
7-4	1235-1241	little	_
7-5	1242-1250	evidence	_
7-6	1251-1254	for	_
7-7	1255-1267	morphometric	_
7-8	1268-1279	differences	_
7-9	1280-1287	between	_
7-10	1288-1291	the	_
7-11	1292-1295	low	_
7-12	1296-1299	and	_
7-13	1300-1304	high	_
7-14	1305-1312	SCZ-RPS	_
7-15	1313-1319	groups	_
7-16	1320-1321	,	_
7-17	1322-1324	we	_
7-18	1325-1333	observed	_
7-19	1334-1336	an	_
7-20	1337-1343	impact	_
7-21	1344-1346	of	_
7-22	1347-1354	SCZ-RPS	_
7-23	1355-1357	on	_
7-24	1358-1363	blood	_
7-25	1364-1370	oxygen	_
7-26	1371-1386	level-dependent	_
7-27	1387-1388	(	_
7-28	1389-1393	BOLD	_
7-29	1394-1395	)	_
7-30	1396-1402	signal	_
7-31	1403-1409	during	_
7-32	1410-1416	reward	_
7-33	1417-1427	processing	_
7-34	1428-1430	in	_
7-35	1431-1434	the	_
7-36	1435-1442	ventral	_
7-37	1443-1451	striatum	_
7-38	1452-1453	(	_
7-39	1454-1471	PFWE-VS-CORRECTED	_
7-40	1472-1473	=	_
7-41	1474-1478	.037	_
7-42	1479-1480	)	_
7-43	1481-1482	,	_
7-44	1483-1484	a	_
7-45	1485-1495	previously	_
7-46	1496-1508	investigated	_
7-47	1509-1516	broader	_
7-48	1517-1531	reward-related	_
7-49	1532-1539	network	_
7-50	1540-1541	(	_
7-51	1542-1561	PFWE-ROIS-CORRECTED	_
7-52	1562-1563	=	_
7-53	1564-1568	.008	_
7-54	1569-1570	)	_
7-55	1571-1572	,	_
7-56	1573-1576	and	_
7-57	1577-1583	across	_
7-58	1584-1587	the	_
7-59	1588-1593	whole	_
7-60	1594-1599	brain	_
7-61	1600-1601	(	_
7-62	1602-1628	PFWE-WHOLE-BRAIN-CORRECTED	_
7-63	1629-1630	=	_
7-64	1631-1635	.013	_
7-65	1636-1637	)	_
7-66	1638-1639	.	_

Text=We also describe the study strategy and discuss specific challenges of RbG for SCZ risk (such as SCZ-RPS related homoscedasticity).
8-1	1640-1642	We	_
8-2	1643-1647	also	_
8-3	1648-1656	describe	_
8-4	1657-1660	the	_
8-5	1661-1666	study	_
8-6	1667-1675	strategy	_
8-7	1676-1679	and	_
8-8	1680-1687	discuss	_
8-9	1688-1696	specific	_
8-10	1697-1707	challenges	_
8-11	1708-1710	of	_
8-12	1711-1714	RbG	_
8-13	1715-1718	for	_
8-14	1719-1722	SCZ	_
8-15	1723-1727	risk	_
8-16	1728-1729	(	_
8-17	1730-1734	such	_
8-18	1735-1737	as	_
8-19	1738-1745	SCZ-RPS	_
8-20	1746-1753	related	_
8-21	1754-1770	homoscedasticity	_
8-22	1771-1772	)	_
8-23	1773-1774	.	_

Text=This study will help to elucidate the behavioral and imaging phenotypes that are associated with SCZ genetic risk.
9-1	1775-1779	This	_
9-2	1780-1785	study	_
9-3	1786-1790	will	_
9-4	1791-1795	help	_
9-5	1796-1798	to	_
9-6	1799-1808	elucidate	_
9-7	1809-1812	the	_
9-8	1813-1823	behavioral	_
9-9	1824-1827	and	_
9-10	1828-1835	imaging	_
9-11	1836-1846	phenotypes	_
9-12	1847-1851	that	_
9-13	1852-1855	are	_
9-14	1856-1866	associated	_
9-15	1867-1871	with	_
9-16	1872-1875	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-17	1876-1883	genetic	_
9-18	1884-1888	risk	_
9-19	1889-1890	.	_

Text=Materials and Methods ALSPAC Participants The broader cohort sample from which we selected individuals consisted of young individuals recruited via the ALSPAC cohort.
10-1	1891-1900	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	1901-1904	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	1905-1912	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	1913-1919	ALSPAC	_
10-5	1920-1932	Participants	_
10-6	1933-1936	The	_
10-7	1937-1944	broader	_
10-8	1945-1951	cohort	_
10-9	1952-1958	sample	_
10-10	1959-1963	from	_
10-11	1964-1969	which	_
10-12	1970-1972	we	_
10-13	1973-1981	selected	_
10-14	1982-1993	individuals	_
10-15	1994-2003	consisted	_
10-16	2004-2006	of	_
10-17	2007-2012	young	_
10-18	2013-2024	individuals	_
10-19	2025-2034	recruited	_
10-20	2035-2038	via	_
10-21	2039-2042	the	_
10-22	2043-2049	ALSPAC	_
10-23	2050-2056	cohort	_
10-24	2057-2058	.	_

Text=This broader cohort consisted of 14062 children born to women residing in the former Avon Health Authority area with an expected delivery date from April 1, 1991 to December 31, 1992 (http: //www.bristol.ac.uk/alspac/; available at http: //www.bristol.ac.uk/alspac/researchers/access/).
11-1	2059-2063	This	_
11-2	2064-2071	broader	_
11-3	2072-2078	cohort	_
11-4	2079-2088	consisted	_
11-5	2089-2091	of	_
11-6	2092-2097	14062	_
11-7	2098-2106	children	_
11-8	2107-2111	born	_
11-9	2112-2114	to	_
11-10	2115-2120	women	_
11-11	2121-2129	residing	_
11-12	2130-2132	in	_
11-13	2133-2136	the	_
11-14	2137-2143	former	_
11-15	2144-2148	Avon	_
11-16	2149-2155	Health	_
11-17	2156-2165	Authority	_
11-18	2166-2170	area	_
11-19	2171-2175	with	_
11-20	2176-2178	an	_
11-21	2179-2187	expected	_
11-22	2188-2196	delivery	_
11-23	2197-2201	date	_
11-24	2202-2206	from	_
11-25	2207-2212	April	_
11-26	2213-2214	1	_
11-27	2215-2216	,	_
11-28	2217-2221	1991	_
11-29	2222-2224	to	_
11-30	2225-2233	December	_
11-31	2234-2236	31	_
11-32	2237-2238	,	_
11-33	2239-2243	1992	_
11-34	2244-2245	(	_
11-35	2246-2250	http	_
11-36	2251-2252	:	_
11-37	2253-2280	//www.bristol.ac.uk/alspac/	_
11-38	2281-2282	;	_
11-39	2283-2292	available	_
11-40	2293-2295	at	_
11-41	2296-2300	http	_
11-42	2301-2302	:	_
11-43	2303-2349	//www.bristol.ac.uk/alspac/researchers/access/	_
11-44	2350-2351	)	_
11-45	2352-2353	.	_

Text=Data were collected periodically from September 6, 1990, and collection is ongoing.
12-1	2354-2358	Data	_
12-2	2359-2363	were	_
12-3	2364-2373	collected	_
12-4	2374-2386	periodically	_
12-5	2387-2391	from	_
12-6	2392-2401	September	_
12-7	2402-2403	6	_
12-8	2404-2405	,	_
12-9	2406-2410	1990	_
12-10	2411-2412	,	_
12-11	2413-2416	and	_
12-12	2417-2427	collection	_
12-13	2428-2430	is	_
12-14	2431-2438	ongoing	_
12-15	2439-2440	.	_

Text=Ethical approval for the study was obtained from the ALSPAC Law and Ethics Committee and the local research ethics committees (listed at http: //www.bristol.ac.uk/alspac/researchers/research-ethics/).
13-1	2441-2448	Ethical	_
13-2	2449-2457	approval	_
13-3	2458-2461	for	_
13-4	2462-2465	the	_
13-5	2466-2471	study	_
13-6	2472-2475	was	_
13-7	2476-2484	obtained	_
13-8	2485-2489	from	_
13-9	2490-2493	the	_
13-10	2494-2500	ALSPAC	_
13-11	2501-2504	Law	_
13-12	2505-2508	and	_
13-13	2509-2515	Ethics	_
13-14	2516-2525	Committee	_
13-15	2526-2529	and	_
13-16	2530-2533	the	_
13-17	2534-2539	local	_
13-18	2540-2548	research	_
13-19	2549-2555	ethics	_
13-20	2556-2566	committees	_
13-21	2567-2568	(	_
13-22	2569-2575	listed	_
13-23	2576-2578	at	_
13-24	2579-2583	http	_
13-25	2584-2585	:	_
13-26	2586-2641	//www.bristol.ac.uk/alspac/researchers/research-ethics/	_
13-27	2642-2643	)	_
13-28	2644-2645	.	_

Text=ALSPAC Participant Genotyping All individuals recruited via the ALSPAC sample were genotyped using the Illumina HumanHap550 quad chip genotyping platforms by 23andme subcontracting the Wellcome Trust Sanger Institute, Cambridge, UK and the Laboratory Corporation of America, Burlington, NC.
14-1	2646-2652	ALSPAC	http://maven.renci.org/NeuroBridge/neurobridge#OpticalSpectroscopy
14-2	2653-2664	Participant	_
14-3	2665-2675	Genotyping	_
14-4	2676-2679	All	_
14-5	2680-2691	individuals	_
14-6	2692-2701	recruited	_
14-7	2702-2705	via	_
14-8	2706-2709	the	_
14-9	2710-2716	ALSPAC	http://maven.renci.org/NeuroBridge/neurobridge#OpticalSpectroscopy
14-10	2717-2723	sample	_
14-11	2724-2728	were	_
14-12	2729-2738	genotyped	_
14-13	2739-2744	using	_
14-14	2745-2748	the	_
14-15	2749-2757	Illumina	_
14-16	2758-2769	HumanHap550	_
14-17	2770-2774	quad	_
14-18	2775-2779	chip	_
14-19	2780-2790	genotyping	_
14-20	2791-2800	platforms	_
14-21	2801-2803	by	_
14-22	2804-2811	23andme	_
14-23	2812-2826	subcontracting	_
14-24	2827-2830	the	_
14-25	2831-2839	Wellcome	_
14-26	2840-2845	Trust	_
14-27	2846-2852	Sanger	_
14-28	2853-2862	Institute	_
14-29	2863-2864	,	_
14-30	2865-2874	Cambridge	_
14-31	2875-2876	,	_
14-32	2877-2879	UK	_
14-33	2880-2883	and	_
14-34	2884-2887	the	_
14-35	2888-2898	Laboratory	_
14-36	2899-2910	Corporation	_
14-37	2911-2913	of	_
14-38	2914-2921	America	_
14-39	2922-2923	,	_
14-40	2924-2934	Burlington	_
14-41	2935-2936	,	_
14-42	2937-2939	NC	_
14-43	2940-2941	.	_

Text=The raw genome-wide data were subjected to standard quality control methods.
15-1	2942-2945	The	_
15-2	2946-2949	raw	_
15-3	2950-2961	genome-wide	_
15-4	2962-2966	data	_
15-5	2967-2971	were	_
15-6	2972-2981	subjected	_
15-7	2982-2984	to	_
15-8	2985-2993	standard	_
15-9	2994-3001	quality	_
15-10	3002-3009	control	_
15-11	3010-3017	methods	_
15-12	3018-3019	.	_

Text=Briefly, individuals were excluded on the basis of gender mismatches; minimal or excessive heterozygosity; disproportionate levels of individual missingness (> 3%) and insufficient sample replication (IBD <0.8).
16-1	3020-3027	Briefly	_
16-2	3028-3029	,	_
16-3	3030-3041	individuals	_
16-4	3042-3046	were	_
16-5	3047-3055	excluded	_
16-6	3056-3058	on	_
16-7	3059-3062	the	_
16-8	3063-3068	basis	_
16-9	3069-3071	of	_
16-10	3072-3078	gender	_
16-11	3079-3089	mismatches	_
16-12	3090-3091	;	_
16-13	3092-3099	minimal	_
16-14	3100-3102	or	_
16-15	3103-3112	excessive	_
16-16	3113-3127	heterozygosity	_
16-17	3128-3129	;	_
16-18	3130-3146	disproportionate	_
16-19	3147-3153	levels	_
16-20	3154-3156	of	_
16-21	3157-3167	individual	_
16-22	3168-3179	missingness	_
16-23	3180-3181	(	_
16-24	3182-3183	>	_
16-25	3184-3185	3	_
16-26	3186-3187	%	_
16-27	3188-3189	)	_
16-28	3190-3193	and	_
16-29	3194-3206	insufficient	_
16-30	3207-3213	sample	_
16-31	3214-3225	replication	_
16-32	3226-3227	(	_
16-33	3228-3231	IBD	_
16-34	3232-3233	<	_
16-35	3234-3237	0.8	_
16-36	3238-3239	)	_
16-37	3240-3241	.	_

Text=Population stratification was assessed by multidimensional scaling analysis and compared with Hapmap II (release 22) European descent (CEU), Han Chinese, Japanese, and Yoruba reference populations; all individuals with non-European ancestry were removed.
17-1	3242-3252	Population	_
17-2	3253-3267	stratification	_
17-3	3268-3271	was	_
17-4	3272-3280	assessed	_
17-5	3281-3283	by	_
17-6	3284-3300	multidimensional	_
17-7	3301-3308	scaling	_
17-8	3309-3317	analysis	_
17-9	3318-3321	and	_
17-10	3322-3330	compared	_
17-11	3331-3335	with	_
17-12	3336-3342	Hapmap	_
17-13	3343-3345	II	_
17-14	3346-3347	(	_
17-15	3348-3355	release	_
17-16	3356-3358	22	_
17-17	3359-3360	)	_
17-18	3361-3369	European	_
17-19	3370-3377	descent	_
17-20	3378-3379	(	_
17-21	3380-3383	CEU	_
17-22	3384-3385	)	_
17-23	3386-3387	,	_
17-24	3388-3391	Han	_
17-25	3392-3399	Chinese	_
17-26	3400-3401	,	_
17-27	3402-3410	Japanese	_
17-28	3411-3412	,	_
17-29	3413-3416	and	_
17-30	3417-3423	Yoruba	_
17-31	3424-3433	reference	_
17-32	3434-3445	populations	_
17-33	3446-3447	;	_
17-34	3448-3451	all	_
17-35	3452-3463	individuals	_
17-36	3464-3468	with	_
17-37	3469-3481	non-European	_
17-38	3482-3490	ancestry	_
17-39	3491-3495	were	_
17-40	3496-3503	removed	_
17-41	3504-3505	.	_

Text=SNPs with a minor allele frequency of <1%, a call rate of <95% or evidence for violations of Hardy-Weinberg equilibrium (P <5E-7) were removed.
18-1	3506-3510	SNPs	_
18-2	3511-3515	with	_
18-3	3516-3517	a	_
18-4	3518-3523	minor	_
18-5	3524-3530	allele	_
18-6	3531-3540	frequency	_
18-7	3541-3543	of	_
18-8	3544-3545	<	_
18-9	3546-3547	1	_
18-10	3548-3549	%	_
18-11	3550-3551	,	_
18-12	3552-3553	a	_
18-13	3554-3558	call	_
18-14	3559-3563	rate	_
18-15	3564-3566	of	_
18-16	3567-3568	<	_
18-17	3569-3571	95	_
18-18	3572-3573	%	_
18-19	3574-3576	or	_
18-20	3577-3585	evidence	_
18-21	3586-3589	for	_
18-22	3590-3600	violations	_
18-23	3601-3603	of	_
18-24	3604-3618	Hardy-Weinberg	_
18-25	3619-3630	equilibrium	_
18-26	3631-3632	(	_
18-27	3633-3634	P	_
18-28	3635-3636	<	_
18-29	3637-3641	5E-7	_
18-30	3642-3643	)	_
18-31	3644-3648	were	_
18-32	3649-3656	removed	_
18-33	3657-3658	.	_

Text=Cryptic relatedness was measured/excluded as proportion of identity by descent (IBD> 0.1).
19-1	3659-3666	Cryptic	_
19-2	3667-3678	relatedness	_
19-3	3679-3682	was	_
19-4	3683-3700	measured/excluded	_
19-5	3701-3703	as	_
19-6	3704-3714	proportion	_
19-7	3715-3717	of	_
19-8	3718-3726	identity	_
19-9	3727-3729	by	_
19-10	3730-3737	descent	_
19-11	3738-3739	(	_
19-12	3740-3743	IBD	_
19-13	3744-3745	>	_
19-14	3746-3749	0.1	_
19-15	3750-3751	)	_
19-16	3752-3753	.	_

Text=Related subjects that passed all other quality control thresholds were retained during subsequent phasing and imputation.
20-1	3754-3761	Related	_
20-2	3762-3770	subjects	_
20-3	3771-3775	that	_
20-4	3776-3782	passed	_
20-5	3783-3786	all	_
20-6	3787-3792	other	_
20-7	3793-3800	quality	_
20-8	3801-3808	control	_
20-9	3809-3819	thresholds	_
20-10	3820-3824	were	_
20-11	3825-3833	retained	_
20-12	3834-3840	during	_
20-13	3841-3851	subsequent	_
20-14	3852-3859	phasing	_
20-15	3860-3863	and	_
20-16	3864-3874	imputation	_
20-17	3875-3876	.	_

Text=Nine thousand one hundred fifteen subjects and 500527 SNPs passed these quality control filters.
21-1	3877-3881	Nine	_
21-2	3882-3890	thousand	_
21-3	3891-3894	one	_
21-4	3895-3902	hundred	_
21-5	3903-3910	fifteen	_
21-6	3911-3919	subjects	_
21-7	3920-3923	and	_
21-8	3924-3930	500527	_
21-9	3931-3935	SNPs	_
21-10	3936-3942	passed	_
21-11	3943-3948	these	_
21-12	3949-3956	quality	_
21-13	3957-3964	control	_
21-14	3965-3972	filters	_
21-15	3973-3974	.	_

Text=We combined 477482 SNP genotypes in common between the sample of mothers and sample of children.
22-1	3975-3977	We	_
22-2	3978-3986	combined	_
22-3	3987-3993	477482	_
22-4	3994-3997	SNP	_
22-5	3998-4007	genotypes	_
22-6	4008-4010	in	_
22-7	4011-4017	common	_
22-8	4018-4025	between	_
22-9	4026-4029	the	_
22-10	4030-4036	sample	_
22-11	4037-4039	of	_
22-12	4040-4047	mothers	_
22-13	4048-4051	and	_
22-14	4052-4058	sample	_
22-15	4059-4061	of	_
22-16	4062-4070	children	_
22-17	4071-4072	.	_

Text=We removed SNPs with genotype missingness above 1% due to poor quality (11396 SNPs removed) and removed a further 321 subjects due to potential ID mismatches, resulting in a data set containing 465740 SNPs.
23-1	4073-4075	We	_
23-2	4076-4083	removed	_
23-3	4084-4088	SNPs	_
23-4	4089-4093	with	_
23-5	4094-4102	genotype	_
23-6	4103-4114	missingness	_
23-7	4115-4120	above	_
23-8	4121-4122	1	_
23-9	4123-4124	%	_
23-10	4125-4128	due	_
23-11	4129-4131	to	_
23-12	4132-4136	poor	_
23-13	4137-4144	quality	_
23-14	4145-4146	(	_
23-15	4147-4152	11396	_
23-16	4153-4157	SNPs	_
23-17	4158-4165	removed	_
23-18	4166-4167	)	_
23-19	4168-4171	and	_
23-20	4172-4179	removed	_
23-21	4180-4181	a	_
23-22	4182-4189	further	_
23-23	4190-4193	321	_
23-24	4194-4202	subjects	_
23-25	4203-4206	due	_
23-26	4207-4209	to	_
23-27	4210-4219	potential	_
23-28	4220-4222	ID	_
23-29	4223-4233	mismatches	_
23-30	4234-4235	,	_
23-31	4236-4245	resulting	_
23-32	4246-4248	in	_
23-33	4249-4250	a	_
23-34	4251-4255	data	_
23-35	4256-4259	set	_
23-36	4260-4270	containing	_
23-37	4271-4277	465740	_
23-38	4278-4282	SNPs	_
23-39	4283-4284	.	_

Text=We estimated haplotypes using ShapeIT (v2.r644) which utilizes relatedness during phasing.
24-1	4285-4287	We	_
24-2	4288-4297	estimated	_
24-3	4298-4308	haplotypes	_
24-4	4309-4314	using	_
24-5	4315-4322	ShapeIT	_
24-6	4323-4324	(	_
24-7	4325-4332	v2.r644	_
24-8	4333-4334	)	_
24-9	4335-4340	which	_
24-10	4341-4349	utilizes	_
24-11	4350-4361	relatedness	_
24-12	4362-4368	during	_
24-13	4369-4376	phasing	_
24-14	4377-4378	.	_

Text=We obtained a phased version of the 1000 genomes reference panel (phase 1, version 3) from the Impute2 reference data repository (phased using ShapeIt v2.r644, haplotype release date Dec 2013).
25-1	4379-4381	We	_
25-2	4382-4390	obtained	_
25-3	4391-4392	a	_
25-4	4393-4399	phased	_
25-5	4400-4407	version	_
25-6	4408-4410	of	_
25-7	4411-4414	the	_
25-8	4415-4419	1000	_
25-9	4420-4427	genomes	_
25-10	4428-4437	reference	_
25-11	4438-4443	panel	_
25-12	4444-4445	(	_
25-13	4446-4451	phase	_
25-14	4452-4453	1	_
25-15	4454-4455	,	_
25-16	4456-4463	version	_
25-17	4464-4465	3	_
25-18	4466-4467	)	_
25-19	4468-4472	from	_
25-20	4473-4476	the	_
25-21	4477-4484	Impute2	_
25-22	4485-4494	reference	_
25-23	4495-4499	data	_
25-24	4500-4510	repository	_
25-25	4511-4512	(	_
25-26	4513-4519	phased	_
25-27	4520-4525	using	_
25-28	4526-4533	ShapeIt	_
25-29	4534-4541	v2.r644	_
25-30	4542-4543	,	_
25-31	4544-4553	haplotype	_
25-32	4554-4561	release	_
25-33	4562-4566	date	_
25-34	4567-4570	Dec	_
25-35	4571-4575	2013	_
25-36	4576-4577	)	_
25-37	4578-4579	.	_

Text=Imputation of the target data was performed using Impute V2.2.2 against the reference panel (all polymorphic SNPs excluding singletons), using all 2186 reference haplotypes (including non-Europeans).
26-1	4580-4590	Imputation	_
26-2	4591-4593	of	_
26-3	4594-4597	the	_
26-4	4598-4604	target	_
26-5	4605-4609	data	_
26-6	4610-4613	was	_
26-7	4614-4623	performed	_
26-8	4624-4629	using	_
26-9	4630-4636	Impute	_
26-10	4637-4643	V2.2.2	_
26-11	4644-4651	against	_
26-12	4652-4655	the	_
26-13	4656-4665	reference	_
26-14	4666-4671	panel	_
26-15	4672-4673	(	_
26-16	4674-4677	all	_
26-17	4678-4689	polymorphic	_
26-18	4690-4694	SNPs	_
26-19	4695-4704	excluding	_
26-20	4705-4715	singletons	_
26-21	4716-4717	)	_
26-22	4718-4719	,	_
26-23	4720-4725	using	_
26-24	4726-4729	all	_
26-25	4730-4734	2186	_
26-26	4735-4744	reference	_
26-27	4745-4755	haplotypes	_
26-28	4756-4757	(	_
26-29	4758-4767	including	_
26-30	4768-4781	non-Europeans	_
26-31	4782-4783	)	_
26-32	4784-4785	.	_

Text=After quality control, a total of 8365 individuals were genotyped and underwent SCZ-RPS calculations.
27-1	4786-4791	After	_
27-2	4792-4799	quality	_
27-3	4800-4807	control	_
27-4	4808-4809	,	_
27-5	4810-4811	a	_
27-6	4812-4817	total	_
27-7	4818-4820	of	_
27-8	4821-4825	8365	_
27-9	4826-4837	individuals	_
27-10	4838-4842	were	_
27-11	4843-4852	genotyped	_
27-12	4853-4856	and	_
27-13	4857-4866	underwent	_
27-14	4867-4874	SCZ-RPS	_
27-15	4875-4887	calculations	_
27-16	4888-4889	.	_

Text=ALSPAC Participant SCZ-RPS Creation Construction of the SCZ-RPS follows the methods described by the International Schizophrenia Consortium, using results from the Psychiatric Genomics Consortium (PGC) SCZ genome-wide association studies (GWAS).
28-1	4890-4896	ALSPAC	_
28-2	4897-4908	Participant	_
28-3	4909-4916	SCZ-RPS	_
28-4	4917-4925	Creation	_
28-5	4926-4938	Construction	_
28-6	4939-4941	of	_
28-7	4942-4945	the	_
28-8	4946-4953	SCZ-RPS	_
28-9	4954-4961	follows	_
28-10	4962-4965	the	_
28-11	4966-4973	methods	_
28-12	4974-4983	described	_
28-13	4984-4986	by	_
28-14	4987-4990	the	_
28-15	4991-5004	International	_
28-16	5005-5018	Schizophrenia	_
28-17	5019-5029	Consortium	_
28-18	5030-5031	,	_
28-19	5032-5037	using	_
28-20	5038-5045	results	_
28-21	5046-5050	from	_
28-22	5051-5054	the	_
28-23	5055-5066	Psychiatric	_
28-24	5067-5075	Genomics	_
28-25	5076-5086	Consortium	_
28-26	5087-5088	(	_
28-27	5089-5092	PGC	_
28-28	5093-5094	)	_
28-29	5095-5098	SCZ	_
28-30	5099-5110	genome-wide	_
28-31	5111-5122	association	_
28-32	5123-5130	studies	_
28-33	5131-5132	(	_
28-34	5133-5137	GWAS	_
28-35	5138-5139	)	_
28-36	5140-5141	.	_

Text=Polygenic scores were calculated for each ALSPAC individual using the “ score ” command in PLINK (version 1.07).
29-1	5142-5151	Polygenic	_
29-2	5152-5158	scores	_
29-3	5159-5163	were	_
29-4	5164-5174	calculated	_
29-5	5175-5178	for	_
29-6	5179-5183	each	_
29-7	5184-5190	ALSPAC	_
29-8	5191-5201	individual	_
29-9	5202-5207	using	_
29-10	5208-5211	the	_
29-11	5212-5213	“	_
29-12	5214-5219	score	_
29-13	5220-5221	”	_
29-14	5222-5229	command	_
29-15	5230-5232	in	_
29-16	5233-5238	PLINK	_
29-17	5239-5240	(	_
29-18	5241-5248	version	_
29-19	5249-5253	1.07	_
29-20	5254-5255	)	_
29-21	5256-5257	.	_

Text=Individual SCZ-RPS were created by summing the number of risk alleles present for each SNP (0, 1, or 2) weighted by the logarithm of each SNP ’ s OR for SCZ from the PGC summary statistics for each individual.
30-1	5258-5268	Individual	_
30-2	5269-5276	SCZ-RPS	_
30-3	5277-5281	were	_
30-4	5282-5289	created	_
30-5	5290-5292	by	_
30-6	5293-5300	summing	_
30-7	5301-5304	the	_
30-8	5305-5311	number	_
30-9	5312-5314	of	_
30-10	5315-5319	risk	_
30-11	5320-5327	alleles	_
30-12	5328-5335	present	_
30-13	5336-5339	for	_
30-14	5340-5344	each	_
30-15	5345-5348	SNP	_
30-16	5349-5350	(	_
30-17	5351-5352	0	_
30-18	5353-5354	,	_
30-19	5355-5356	1	_
30-20	5357-5358	,	_
30-21	5359-5361	or	_
30-22	5362-5363	2	_
30-23	5364-5365	)	_
30-24	5366-5374	weighted	_
30-25	5375-5377	by	_
30-26	5378-5381	the	_
30-27	5382-5391	logarithm	_
30-28	5392-5394	of	_
30-29	5395-5399	each	_
30-30	5400-5403	SNP	_
30-31	5404-5405	’	_
30-32	5406-5407	s	_
30-33	5408-5410	OR	_
30-34	5411-5414	for	_
30-35	5415-5418	SCZ	_
30-36	5419-5423	from	_
30-37	5424-5427	the	_
30-38	5428-5431	PGC	_
30-39	5432-5439	summary	_
30-40	5440-5450	statistics	_
30-41	5451-5454	for	_
30-42	5455-5459	each	_
30-43	5460-5470	individual	_
30-44	5471-5472	.	_

Text=Our SCZ-RPS–based RbG was solely based upon a RPS generated from SNPs with a GWAS training-set P ≤.
31-1	5473-5476	Our	_
31-2	5477-5490	SCZ-RPS–based	_
31-3	5491-5494	RbG	_
31-4	5495-5498	was	_
31-5	5499-5505	solely	_
31-6	5506-5511	based	_
31-7	5512-5516	upon	_
31-8	5517-5518	a	_
31-9	5519-5522	RPS	_
31-10	5523-5532	generated	_
31-11	5533-5537	from	_
31-12	5538-5542	SNPs	_
31-13	5543-5547	with	_
31-14	5548-5549	a	_
31-15	5550-5554	GWAS	_
31-16	5555-5567	training-set	_
31-17	5568-5569	P	_
31-18	5570-5571	≤	_
31-19	5572-5573	.	_

Text=05 threshold, approximately 5% of all imputed SNPs.
32-1	5574-5576	05	_
32-2	5577-5586	threshold	_
32-3	5587-5588	,	_
32-4	5589-5602	approximately	_
32-5	5603-5604	5	_
32-6	5605-5606	%	_
32-7	5607-5609	of	_
32-8	5610-5613	all	_
32-9	5614-5621	imputed	_
32-10	5622-5626	SNPs	_
32-11	5627-5628	.	_

Text=This threshold was specifically chosen as it captures the most SCZ liability (most variance explained) in the primary RPS analysis using training data/summary statistics derived from the largest SCZ GWAS of 34241 SCZ cases and 45604 controls.
33-1	5629-5633	This	_
33-2	5634-5643	threshold	_
33-3	5644-5647	was	_
33-4	5648-5660	specifically	_
33-5	5661-5667	chosen	_
33-6	5668-5670	as	_
33-7	5671-5673	it	_
33-8	5674-5682	captures	_
33-9	5683-5686	the	_
33-10	5687-5691	most	_
33-11	5692-5695	SCZ	_
33-12	5696-5705	liability	_
33-13	5706-5707	(	_
33-14	5708-5712	most	_
33-15	5713-5721	variance	_
33-16	5722-5731	explained	_
33-17	5732-5733	)	_
33-18	5734-5736	in	_
33-19	5737-5740	the	_
33-20	5741-5748	primary	_
33-21	5749-5752	RPS	_
33-22	5753-5761	analysis	_
33-23	5762-5767	using	_
33-24	5768-5776	training	_
33-25	5777-5789	data/summary	_
33-26	5790-5800	statistics	_
33-27	5801-5808	derived	_
33-28	5809-5813	from	_
33-29	5814-5817	the	_
33-30	5818-5825	largest	_
33-31	5826-5829	SCZ	_
33-32	5830-5834	GWAS	_
33-33	5835-5837	of	_
33-34	5838-5843	34241	_
33-35	5844-5847	SCZ	_
33-36	5848-5853	cases	_
33-37	5854-5857	and	_
33-38	5858-5863	45604	_
33-39	5864-5872	controls	_
33-40	5873-5874	.	_

Text=SCZ-RPS Stratification and Cardiff Subsample From the 8365 individuals who were considered for SCZ-RPS calculation, a total of 197 individuals (99 with low SCZ-RPS, 98 with high SCZ-RPS) participated in a battery of psychometric/neuroimaging paradigms, previously linked to the etiology of SCZ.
34-1	5875-5882	SCZ-RPS	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
34-2	5883-5897	Stratification	_
34-3	5898-5901	and	_
34-4	5902-5909	Cardiff	_
34-5	5910-5919	Subsample	_
34-6	5920-5924	From	_
34-7	5925-5928	the	_
34-8	5929-5933	8365	_
34-9	5934-5945	individuals	_
34-10	5946-5949	who	_
34-11	5950-5954	were	_
34-12	5955-5965	considered	_
34-13	5966-5969	for	_
34-14	5970-5977	SCZ-RPS	_
34-15	5978-5989	calculation	_
34-16	5990-5991	,	_
34-17	5992-5993	a	_
34-18	5994-5999	total	_
34-19	6000-6002	of	_
34-20	6003-6006	197	_
34-21	6007-6018	individuals	_
34-22	6019-6020	(	_
34-23	6021-6023	99	_
34-24	6024-6028	with	_
34-25	6029-6032	low	_
34-26	6033-6040	SCZ-RPS	_
34-27	6041-6042	,	_
34-28	6043-6045	98	_
34-29	6046-6050	with	_
34-30	6051-6055	high	_
34-31	6056-6063	SCZ-RPS	_
34-32	6064-6065	)	_
34-33	6066-6078	participated	_
34-34	6079-6081	in	_
34-35	6082-6083	a	_
34-36	6084-6091	battery	_
34-37	6092-6094	of	_
34-38	6095-6120	psychometric/neuroimaging	_
34-39	6121-6130	paradigms	_
34-40	6131-6132	,	_
34-41	6133-6143	previously	_
34-42	6144-6150	linked	_
34-43	6151-6153	to	_
34-44	6154-6157	the	_
34-45	6158-6166	etiology	_
34-46	6167-6169	of	_
34-47	6170-6173	SCZ	_
34-48	6174-6175	.	_

Text=A further 104 individuals declined our invitation (by written reply) to participate in the study (low SCZ-RPS [n = 40]; high SCZ-RPS [n = 64]), conforming to prior observations that SCZ-RPS is related to nonparticipation.
35-1	6176-6177	A	_
35-2	6178-6185	further	_
35-3	6186-6189	104	_
35-4	6190-6201	individuals	_
35-5	6202-6210	declined	_
35-6	6211-6214	our	_
35-7	6215-6225	invitation	_
35-8	6226-6227	(	_
35-9	6228-6230	by	_
35-10	6231-6238	written	_
35-11	6239-6244	reply	_
35-12	6245-6246	)	_
35-13	6247-6249	to	_
35-14	6250-6261	participate	_
35-15	6262-6264	in	_
35-16	6265-6268	the	_
35-17	6269-6274	study	_
35-18	6275-6276	(	_
35-19	6277-6280	low	_
35-20	6281-6288	SCZ-RPS	_
35-21	6289-6290	[	_
35-22	6291-6292	n	_
35-23	6293-6294	=	_
35-24	6295-6297	40	_
35-25	6298-6299	]	_
35-26	6300-6301	;	_
35-27	6302-6306	high	_
35-28	6307-6314	SCZ-RPS	_
35-29	6315-6316	[	_
35-30	6317-6318	n	_
35-31	6319-6320	=	_
35-32	6321-6323	64	_
35-33	6324-6325	]	_
35-34	6326-6327	)	_
35-35	6328-6329	,	_
35-36	6330-6340	conforming	_
35-37	6341-6343	to	_
35-38	6344-6349	prior	_
35-39	6350-6362	observations	_
35-40	6363-6367	that	_
35-41	6368-6375	SCZ-RPS	_
35-42	6376-6378	is	_
35-43	6379-6386	related	_
35-44	6387-6389	to	_
35-45	6390-6406	nonparticipation	_
35-46	6407-6408	.	_

Text=Researchers were blind to which tail of the SCZ-RPS distribution each individual was selected from during the data collection and processing.
36-1	6409-6420	Researchers	_
36-2	6421-6425	were	_
36-3	6426-6431	blind	_
36-4	6432-6434	to	_
36-5	6435-6440	which	_
36-6	6441-6445	tail	_
36-7	6446-6448	of	_
36-8	6449-6452	the	_
36-9	6453-6460	SCZ-RPS	_
36-10	6461-6473	distribution	_
36-11	6474-6478	each	_
36-12	6479-6489	individual	_
36-13	6490-6493	was	_
36-14	6494-6502	selected	_
36-15	6503-6507	from	_
36-16	6508-6514	during	_
36-17	6515-6518	the	_
36-18	6519-6523	data	_
36-19	6524-6534	collection	_
36-20	6535-6538	and	_
36-21	6539-6549	processing	_
36-22	6550-6551	.	_

Text=All participants provided written informed consent.
37-1	6552-6555	All	_
37-2	6556-6568	participants	_
37-3	6569-6577	provided	_
37-4	6578-6585	written	_
37-5	6586-6594	informed	_
37-6	6595-6602	consent	_
37-7	6603-6604	.	_

Text=The SCZ-RPS groups were matched for gender (low SCZ-RPS: 52 female, 47 male; high SCZ-RPS: 52 female, 46 male).
38-1	6605-6608	The	_
38-2	6609-6616	SCZ-RPS	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
38-3	6617-6623	groups	_
38-4	6624-6628	were	_
38-5	6629-6636	matched	_
38-6	6637-6640	for	_
38-7	6641-6647	gender	_
38-8	6648-6649	(	_
38-9	6650-6653	low	_
38-10	6654-6661	SCZ-RPS	_
38-11	6662-6663	:	_
38-12	6664-6666	52	_
38-13	6667-6673	female	_
38-14	6674-6675	,	_
38-15	6676-6678	47	_
38-16	6679-6683	male	_
38-17	6684-6685	;	_
38-18	6686-6690	high	_
38-19	6691-6698	SCZ-RPS	_
38-20	6699-6700	:	_
38-21	6701-6703	52	_
38-22	6704-6710	female	_
38-23	6711-6712	,	_
38-24	6713-6715	46	_
38-25	6716-6720	male	_
38-26	6721-6722	)	_
38-27	6723-6724	.	_

Text=A Priori Power Analysis Using the RbG approach, we estimated we had> 80% power to detect an relatively small effect (R2>.03), at a conservative alpha level (alpha> 0.001); see supplementary methods S1 and supplementary figure S1 for further details.
39-1	6725-6726	A	_
39-2	6727-6733	Priori	_
39-3	6734-6739	Power	_
39-4	6740-6748	Analysis	_
39-5	6749-6754	Using	_
39-6	6755-6758	the	_
39-7	6759-6762	RbG	_
39-8	6763-6771	approach	_
39-9	6772-6773	,	_
39-10	6774-6776	we	_
39-11	6777-6786	estimated	_
39-12	6787-6789	we	_
39-13	6790-6793	had	_
39-14	6794-6795	>	_
39-15	6796-6798	80	_
39-16	6799-6800	%	_
39-17	6801-6806	power	_
39-18	6807-6809	to	_
39-19	6810-6816	detect	_
39-20	6817-6819	an	_
39-21	6820-6830	relatively	_
39-22	6831-6836	small	_
39-23	6837-6843	effect	_
39-24	6844-6845	(	_
39-25	6846-6848	R2	_
39-26	6849-6850	>	_
39-27	6851-6854	.03	_
39-28	6855-6856	)	_
39-29	6857-6858	,	_
39-30	6859-6861	at	_
39-31	6862-6863	a	_
39-32	6864-6876	conservative	_
39-33	6877-6882	alpha	_
39-34	6883-6888	level	_
39-35	6889-6890	(	_
39-36	6891-6896	alpha	_
39-37	6897-6898	>	_
39-38	6899-6904	0.001	_
39-39	6905-6906	)	_
39-40	6907-6908	;	_
39-41	6909-6912	see	_
39-42	6913-6926	supplementary	_
39-43	6927-6934	methods	_
39-44	6935-6937	S1	_
39-45	6938-6941	and	_
39-46	6942-6955	supplementary	_
39-47	6956-6962	figure	_
39-48	6963-6965	S1	_
39-49	6966-6969	for	_
39-50	6970-6977	further	_
39-51	6978-6985	details	_
39-52	6986-6987	.	_

Text=Psychotic Experiences and Cognition The semi-structured Psychosis-Like Symptom Interview was used to assess psychotic experiences (hallucinations, delusions, or experiences of thought interference) at 18 years of age.
40-1	6988-6997	Psychotic	_
40-2	6998-7009	Experiences	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
40-3	7010-7013	and	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
40-4	7014-7023	Cognition	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
40-5	7024-7027	The	_
40-6	7028-7043	semi-structured	_
40-7	7044-7058	Psychosis-Like	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
40-8	7059-7066	Symptom	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
40-9	7067-7076	Interview	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
40-10	7077-7080	was	_
40-11	7081-7085	used	_
40-12	7086-7088	to	_
40-13	7089-7095	assess	_
40-14	7096-7105	psychotic	_
40-15	7106-7117	experiences	_
40-16	7118-7119	(	_
40-17	7120-7134	hallucinations	_
40-18	7135-7136	,	_
40-19	7137-7146	delusions	_
40-20	7147-7148	,	_
40-21	7149-7151	or	_
40-22	7152-7163	experiences	_
40-23	7164-7166	of	_
40-24	7167-7174	thought	_
40-25	7175-7187	interference	_
40-26	7188-7189	)	_
40-27	7190-7192	at	_
40-28	7193-7195	18	_
40-29	7196-7201	years	_
40-30	7202-7204	of	_
40-31	7205-7208	age	_
40-32	7209-7210	.	_

Text=Individuals were deemed to have a psychotic experience if rated as having 1 or more suspected and/or definite psychotic experiences at 18 years of age (pliks18).
41-1	7211-7222	Individuals	_
41-2	7223-7227	were	_
41-3	7228-7234	deemed	_
41-4	7235-7237	to	_
41-5	7238-7242	have	_
41-6	7243-7244	a	_
41-7	7245-7254	psychotic	_
41-8	7255-7265	experience	_
41-9	7266-7268	if	_
41-10	7269-7274	rated	_
41-11	7275-7277	as	_
41-12	7278-7284	having	_
41-13	7285-7286	1	_
41-14	7287-7289	or	_
41-15	7290-7294	more	_
41-16	7295-7304	suspected	_
41-17	7305-7311	and/or	_
41-18	7312-7320	definite	_
41-19	7321-7330	psychotic	_
41-20	7331-7342	experiences	_
41-21	7343-7345	at	_
41-22	7346-7348	18	_
41-23	7349-7354	years	_
41-24	7355-7357	of	_
41-25	7358-7361	age	_
41-26	7362-7363	(	_
41-27	7364-7371	pliks18	_
41-28	7372-7373	)	_
41-29	7374-7375	.	_

Text=Individuals were administered the short form Wechsler Intelligence Scale for Children (WISC-III) at 8 years of age.
42-1	7376-7387	Individuals	_
42-2	7388-7392	were	_
42-3	7393-7405	administered	_
42-4	7406-7409	the	_
42-5	7410-7415	short	http://maven.renci.org/NeuroBridge/neurobridge#DeathCertificate
42-6	7416-7420	form	http://maven.renci.org/NeuroBridge/neurobridge#DeathCertificate
42-7	7421-7429	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
42-8	7430-7442	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
42-9	7443-7448	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
42-10	7449-7452	for	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
42-11	7453-7461	Children	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
42-12	7462-7463	(	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
42-13	7464-7472	WISC-III	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
42-14	7473-7474	)	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
42-15	7475-7477	at	_
42-16	7478-7479	8	_
42-17	7480-7485	years	_
42-18	7486-7488	of	_
42-19	7489-7492	age	_
42-20	7493-7494	.	_

Text=Scores for verbal, performance, and total IQ were taken forward for SCZ-RPS regression analysis.
43-1	7495-7501	Scores	_
43-2	7502-7505	for	_
43-3	7506-7512	verbal	_
43-4	7513-7514	,	_
43-5	7515-7526	performance	_
43-6	7527-7528	,	_
43-7	7529-7532	and	_
43-8	7533-7538	total	_
43-9	7539-7541	IQ	_
43-10	7542-7546	were	_
43-11	7547-7552	taken	_
43-12	7553-7560	forward	_
43-13	7561-7564	for	_
43-14	7565-7572	SCZ-RPS	_
43-15	7573-7583	regression	_
43-16	7584-7592	analysis	_
43-17	7593-7594	.	_

Text=Statistical Analysis Associations between SCZ-RPS groups and psychotic experiences were explored using Firth ’ s Bias-Reduced Logistic Regression via the logistf package in R. This approach computes confidence intervals computed by penalized profile likelihood to control for rare events.
44-1	7595-7606	Statistical	_
44-2	7607-7615	Analysis	_
44-3	7616-7628	Associations	_
44-4	7629-7636	between	_
44-5	7637-7644	SCZ-RPS	_
44-6	7645-7651	groups	_
44-7	7652-7655	and	_
44-8	7656-7665	psychotic	_
44-9	7666-7677	experiences	_
44-10	7678-7682	were	_
44-11	7683-7691	explored	_
44-12	7692-7697	using	_
44-13	7698-7703	Firth	_
44-14	7704-7705	’	_
44-15	7706-7707	s	_
44-16	7708-7720	Bias-Reduced	_
44-17	7721-7729	Logistic	_
44-18	7730-7740	Regression	_
44-19	7741-7744	via	_
44-20	7745-7748	the	_
44-21	7749-7756	logistf	_
44-22	7757-7764	package	_
44-23	7765-7767	in	_
44-24	7768-7770	R.	_
44-25	7771-7775	This	_
44-26	7776-7784	approach	_
44-27	7785-7793	computes	_
44-28	7794-7804	confidence	_
44-29	7805-7814	intervals	_
44-30	7815-7823	computed	_
44-31	7824-7826	by	_
44-32	7827-7836	penalized	_
44-33	7837-7844	profile	_
44-34	7845-7855	likelihood	_
44-35	7856-7858	to	_
44-36	7859-7866	control	_
44-37	7867-7870	for	_
44-38	7871-7875	rare	_
44-39	7876-7882	events	_
44-40	7883-7884	.	_

Text=For WISC-III, Verbal, Performance, and Total IQ from the WISC were regressed against SCZ-RPS in a series of linear models.
45-1	7885-7888	For	_
45-2	7889-7897	WISC-III	_
45-3	7898-7899	,	_
45-4	7900-7906	Verbal	_
45-5	7907-7908	,	_
45-6	7909-7920	Performance	_
45-7	7921-7922	,	_
45-8	7923-7926	and	_
45-9	7927-7932	Total	_
45-10	7933-7935	IQ	_
45-11	7936-7940	from	_
45-12	7941-7944	the	_
45-13	7945-7949	WISC	_
45-14	7950-7954	were	_
45-15	7955-7964	regressed	_
45-16	7965-7972	against	_
45-17	7973-7980	SCZ-RPS	_
45-18	7981-7983	in	_
45-19	7984-7985	a	_
45-20	7986-7992	series	_
45-21	7993-7995	of	_
45-22	7996-8002	linear	_
45-23	8003-8009	models	_
45-24	8010-8011	.	_

Text=Gender was added into each model as a regressor in all cases.
46-1	8012-8018	Gender	_
46-2	8019-8022	was	_
46-3	8023-8028	added	_
46-4	8029-8033	into	_
46-5	8034-8038	each	_
46-6	8039-8044	model	_
46-7	8045-8047	as	_
46-8	8048-8049	a	_
46-9	8050-8059	regressor	_
46-10	8060-8062	in	_
46-11	8063-8066	all	_
46-12	8067-8072	cases	_
46-13	8073-8074	.	_

Text=Structural Imaging Preprocessing and Analysis Structural brain scans were acquired for each individual using a 3T GT HDx system at Cardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology, Cardiff University.
47-1	8075-8085	Structural	_
47-2	8086-8093	Imaging	_
47-3	8094-8107	Preprocessing	_
47-4	8108-8111	and	_
47-5	8112-8120	Analysis	_
47-6	8121-8131	Structural	_
47-7	8132-8137	brain	_
47-8	8138-8143	scans	_
47-9	8144-8148	were	_
47-10	8149-8157	acquired	_
47-11	8158-8161	for	_
47-12	8162-8166	each	_
47-13	8167-8177	individual	_
47-14	8178-8183	using	_
47-15	8184-8185	a	_
47-16	8186-8188	3T	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
47-17	8189-8191	GT	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
47-18	8192-8195	HDx	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
47-19	8196-8202	system	_
47-20	8203-8205	at	_
47-21	8206-8213	Cardiff	_
47-22	8214-8224	University	_
47-23	8225-8230	Brain	_
47-24	8231-8239	Research	_
47-25	8240-8247	Imaging	_
47-26	8248-8254	Centre	_
47-27	8255-8256	(	_
47-28	8257-8263	CUBRIC	_
47-29	8264-8265	)	_
47-30	8266-8267	,	_
47-31	8268-8274	School	_
47-32	8275-8277	of	_
47-33	8278-8288	Psychology	_
47-34	8289-8290	,	_
47-35	8291-8298	Cardiff	_
47-36	8299-8309	University	_
47-37	8310-8311	.	_

Text=High-resolution 3-dimensional T1-weighted images were acquired using a 3-dimensional fast spoiled gradient echo sequence (FSPGR) with contiguous sagittal slices of 1 mm thickness (TR 7.9 s, TE 3.0 ms, TI 450 ms, flip angle 20°, FOV 256 mm × 256 mm × 176 mm to yield 1 mm isotropic voxel resolution images.
48-1	8312-8327	High-resolution	_
48-2	8328-8341	3-dimensional	http://maven.renci.org/NeuroBridge/neurobridge#Immunoelectrophoresis
48-3	8342-8353	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
48-4	8354-8360	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
48-5	8361-8365	were	_
48-6	8366-8374	acquired	_
48-7	8375-8380	using	_
48-8	8381-8382	a	_
48-9	8383-8396	3-dimensional	_
48-10	8397-8401	fast	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
48-11	8402-8409	spoiled	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
48-12	8410-8418	gradient	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
48-13	8419-8423	echo	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
48-14	8424-8432	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
48-15	8433-8434	(	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
48-16	8435-8440	FSPGR	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
48-17	8441-8442	)	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
48-18	8443-8447	with	_
48-19	8448-8458	contiguous	_
48-20	8459-8467	sagittal	_
48-21	8468-8474	slices	_
48-22	8475-8477	of	_
48-23	8478-8479	1	_
48-24	8480-8482	mm	_
48-25	8483-8492	thickness	_
48-26	8493-8494	(	_
48-27	8495-8497	TR	_
48-28	8498-8501	7.9	_
48-29	8502-8503	s	_
48-30	8504-8505	,	_
48-31	8506-8508	TE	_
48-32	8509-8512	3.0	_
48-33	8513-8515	ms	_
48-34	8516-8517	,	_
48-35	8518-8520	TI	_
48-36	8521-8524	450	_
48-37	8525-8527	ms	_
48-38	8528-8529	,	_
48-39	8530-8534	flip	_
48-40	8535-8540	angle	_
48-41	8541-8544	20°	_
48-42	8545-8546	,	_
48-43	8547-8550	FOV	_
48-44	8551-8554	256	_
48-45	8555-8557	mm	_
48-46	8558-8559	×	_
48-47	8560-8563	256	_
48-48	8564-8566	mm	_
48-49	8567-8568	×	_
48-50	8569-8572	176	_
48-51	8573-8575	mm	_
48-52	8576-8578	to	_
48-53	8579-8584	yield	_
48-54	8585-8586	1	_
48-55	8587-8589	mm	_
48-56	8590-8599	isotropic	_
48-57	8600-8605	voxel	_
48-58	8606-8616	resolution	_
48-59	8617-8623	images	_
48-60	8624-8625	.	_

Text=Cortical and subcortical segmentations for each subject were estimated with well-validated segmentation software FreeSurfer version 6.0.
49-1	8626-8634	Cortical	_
49-2	8635-8638	and	_
49-3	8639-8650	subcortical	_
49-4	8651-8664	segmentations	_
49-5	8665-8668	for	_
49-6	8669-8673	each	_
49-7	8674-8681	subject	_
49-8	8682-8686	were	_
49-9	8687-8696	estimated	_
49-10	8697-8701	with	_
49-11	8702-8716	well-validated	_
49-12	8717-8729	segmentation	_
49-13	8730-8738	software	_
49-14	8739-8749	FreeSurfer	_
49-15	8750-8757	version	_
49-16	8758-8761	6.0	_
49-17	8762-8763	.	_

Text=In alignment with ENIGMA analysis strategies in SCZ and genomics, we explored (1) subcortical volume (mm3) (2) cortical (a) thickness (mm) and (b) surface area (mm2).
50-1	8764-8766	In	_
50-2	8767-8776	alignment	_
50-3	8777-8781	with	_
50-4	8782-8788	ENIGMA	_
50-5	8789-8797	analysis	_
50-6	8798-8808	strategies	_
50-7	8809-8811	in	_
50-8	8812-8815	SCZ	_
50-9	8816-8819	and	_
50-10	8820-8828	genomics	_
50-11	8829-8830	,	_
50-12	8831-8833	we	_
50-13	8834-8842	explored	_
50-14	8843-8844	(	_
50-15	8845-8846	1	_
50-16	8847-8848	)	_
50-17	8849-8860	subcortical	_
50-18	8861-8867	volume	_
50-19	8868-8869	(	_
50-20	8870-8873	mm3	_
50-21	8874-8875	)	_
50-22	8876-8877	(	_
50-23	8878-8879	2	_
50-24	8880-8881	)	_
50-25	8882-8890	cortical	_
50-26	8891-8892	(	_
50-27	8893-8894	a	_
50-28	8895-8896	)	_
50-29	8897-8906	thickness	_
50-30	8907-8908	(	_
50-31	8909-8911	mm	_
50-32	8912-8913	)	_
50-33	8914-8917	and	_
50-34	8918-8919	(	_
50-35	8920-8921	b	_
50-36	8922-8923	)	_
50-37	8924-8931	surface	_
50-38	8932-8936	area	_
50-39	8937-8938	(	_
50-40	8939-8942	mm2	_
50-41	8943-8944	)	_
50-42	8945-8946	.	_

Text=Segmentations of 68 (34 left/right) cortical gray matter regions were created based on the Desikan–Killiany atlas and 7 subcortical regions (as well as the hemispheric total intracranial volume, average cortical thickness, and surface area).
51-1	8947-8960	Segmentations	_
51-2	8961-8963	of	_
51-3	8964-8966	68	_
51-4	8967-8968	(	_
51-5	8969-8971	34	_
51-6	8972-8982	left/right	_
51-7	8983-8984	)	_
51-8	8985-8993	cortical	_
51-9	8994-8998	gray	_
51-10	8999-9005	matter	_
51-11	9006-9013	regions	_
51-12	9014-9018	were	_
51-13	9019-9026	created	_
51-14	9027-9032	based	_
51-15	9033-9035	on	_
51-16	9036-9039	the	_
51-17	9040-9056	Desikan–Killiany	_
51-18	9057-9062	atlas	_
51-19	9063-9066	and	_
51-20	9067-9068	7	_
51-21	9069-9080	subcortical	_
51-22	9081-9088	regions	_
51-23	9089-9090	(	_
51-24	9091-9093	as	_
51-25	9094-9098	well	_
51-26	9099-9101	as	_
51-27	9102-9105	the	_
51-28	9106-9117	hemispheric	_
51-29	9118-9123	total	_
51-30	9124-9136	intracranial	_
51-31	9137-9143	volume	_
51-32	9144-9145	,	_
51-33	9146-9153	average	_
51-34	9154-9162	cortical	_
51-35	9163-9172	thickness	_
51-36	9173-9174	,	_
51-37	9175-9178	and	_
51-38	9179-9186	surface	_
51-39	9187-9191	area	_
51-40	9192-9193	)	_
51-41	9194-9195	.	_

Text=Segmented subcortical and cortical regions were visually inspected and statistically evaluated for outliers following standardized ENIGMA protocols (http: //enigma.ini.usc.edu/protocols/imaging-protocols).
52-1	9196-9205	Segmented	_
52-2	9206-9217	subcortical	_
52-3	9218-9221	and	_
52-4	9222-9230	cortical	_
52-5	9231-9238	regions	_
52-6	9239-9243	were	_
52-7	9244-9252	visually	_
52-8	9253-9262	inspected	_
52-9	9263-9266	and	_
52-10	9267-9280	statistically	_
52-11	9281-9290	evaluated	_
52-12	9291-9294	for	_
52-13	9295-9303	outliers	_
52-14	9304-9313	following	_
52-15	9314-9326	standardized	_
52-16	9327-9333	ENIGMA	_
52-17	9334-9343	protocols	_
52-18	9344-9345	(	_
52-19	9346-9350	http	_
52-20	9351-9352	:	_
52-21	9353-9401	//enigma.ini.usc.edu/protocols/imaging-protocols	_
52-22	9402-9403	)	_
52-23	9404-9405	.	_

Text=For the statistical analysis, we averaged each segmentation/parcellation across hemispheres.
53-1	9406-9409	For	_
53-2	9410-9413	the	_
53-3	9414-9425	statistical	_
53-4	9426-9434	analysis	_
53-5	9435-9436	,	_
53-6	9437-9439	we	_
53-7	9440-9448	averaged	_
53-8	9449-9453	each	_
53-9	9454-9479	segmentation/parcellation	_
53-10	9480-9486	across	_
53-11	9487-9498	hemispheres	_
53-12	9499-9500	.	_

Text=Each ROI was regressed against SCZ-RPS group (low/high) with gender & ICV added as covariates.
54-1	9501-9505	Each	_
54-2	9506-9509	ROI	_
54-3	9510-9513	was	_
54-4	9514-9523	regressed	_
54-5	9524-9531	against	_
54-6	9532-9539	SCZ-RPS	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
54-7	9540-9545	group	_
54-8	9546-9547	(	_
54-9	9548-9556	low/high	_
54-10	9557-9558	)	_
54-11	9559-9563	with	_
54-12	9564-9570	gender	_
54-13	9571-9572	&	_
54-14	9573-9576	ICV	_
54-15	9577-9582	added	_
54-16	9583-9585	as	_
54-17	9586-9596	covariates	_
54-18	9597-9598	.	_

Text=Age was not included as a covariate as all participants were born in the same year.
55-1	9599-9602	Age	_
55-2	9603-9606	was	_
55-3	9607-9610	not	_
55-4	9611-9619	included	_
55-5	9620-9622	as	_
55-6	9623-9624	a	_
55-7	9625-9634	covariate	_
55-8	9635-9637	as	_
55-9	9638-9641	all	_
55-10	9642-9654	participants	_
55-11	9655-9659	were	_
55-12	9660-9664	born	_
55-13	9665-9667	in	_
55-14	9668-9671	the	_
55-15	9672-9676	same	_
55-16	9677-9681	year	_
55-17	9682-9683	.	_

Text=Functional Imaging Acquisition and Preprocessing Gradient echoplanar imaging data were acquired for each subject on the same 3T GT HDx system with an 8-channel receiver at CUBRIC (Cardiff University Brain Research Imaging Centre), School of Psychology, Cardiff University (parameters: 35 slices, slice thickness; 3 mm/1 mm gap, acquisition matrix; 64 × 64; FOV; 220 mm, TR 2000 ms, TE 35 ms, flip angle 90°, acceleration [ASSET] factor; 2).
56-1	9684-9694	Functional	_
56-2	9695-9702	Imaging	_
56-3	9703-9714	Acquisition	_
56-4	9715-9718	and	_
56-5	9719-9732	Preprocessing	_
56-6	9733-9741	Gradient	_
56-7	9742-9752	echoplanar	_
56-8	9753-9760	imaging	_
56-9	9761-9765	data	_
56-10	9766-9770	were	_
56-11	9771-9779	acquired	_
56-12	9780-9783	for	_
56-13	9784-9788	each	_
56-14	9789-9796	subject	_
56-15	9797-9799	on	_
56-16	9800-9803	the	_
56-17	9804-9808	same	_
56-18	9809-9811	3T	_
56-19	9812-9814	GT	_
56-20	9815-9818	HDx	_
56-21	9819-9825	system	_
56-22	9826-9830	with	_
56-23	9831-9833	an	_
56-24	9834-9843	8-channel	_
56-25	9844-9852	receiver	_
56-26	9853-9855	at	_
56-27	9856-9862	CUBRIC	_
56-28	9863-9864	(	_
56-29	9865-9872	Cardiff	_
56-30	9873-9883	University	_
56-31	9884-9889	Brain	_
56-32	9890-9898	Research	_
56-33	9899-9906	Imaging	_
56-34	9907-9913	Centre	_
56-35	9914-9915	)	_
56-36	9916-9917	,	_
56-37	9918-9924	School	_
56-38	9925-9927	of	_
56-39	9928-9938	Psychology	_
56-40	9939-9940	,	_
56-41	9941-9948	Cardiff	_
56-42	9949-9959	University	_
56-43	9960-9961	(	_
56-44	9962-9972	parameters	_
56-45	9973-9974	:	_
56-46	9975-9977	35	_
56-47	9978-9984	slices	_
56-48	9985-9986	,	_
56-49	9987-9992	slice	_
56-50	9993-10002	thickness	_
56-51	10003-10004	;	_
56-52	10005-10006	3	_
56-53	10007-10011	mm/1	_
56-54	10012-10014	mm	_
56-55	10015-10018	gap	_
56-56	10019-10020	,	_
56-57	10021-10032	acquisition	_
56-58	10033-10039	matrix	_
56-59	10040-10041	;	_
56-60	10042-10044	64	_
56-61	10045-10046	×	_
56-62	10047-10049	64	_
56-63	10050-10051	;	_
56-64	10052-10055	FOV	_
56-65	10056-10057	;	_
56-66	10058-10061	220	_
56-67	10062-10064	mm	_
56-68	10065-10066	,	_
56-69	10067-10069	TR	_
56-70	10070-10074	2000	_
56-71	10075-10077	ms	_
56-72	10078-10079	,	_
56-73	10080-10082	TE	_
56-74	10083-10085	35	_
56-75	10086-10088	ms	_
56-76	10089-10090	,	_
56-77	10091-10095	flip	_
56-78	10096-10101	angle	_
56-79	10102-10105	90°	_
56-80	10106-10107	,	_
56-81	10108-10120	acceleration	_
56-82	10121-10122	[	_
56-83	10123-10128	ASSET	_
56-84	10129-10130	]	_
56-85	10131-10137	factor	_
56-86	10138-10139	;	_
56-87	10140-10141	2	_
56-88	10142-10143	)	_
56-89	10144-10145	.	_

Text=All functional images were first motion scrubbed, where TRs with a frame wise displacement> 0.9 were removed, as previously recommended.
57-1	10146-10149	All	_
57-2	10150-10160	functional	_
57-3	10161-10167	images	_
57-4	10168-10172	were	_
57-5	10173-10178	first	_
57-6	10179-10185	motion	_
57-7	10186-10194	scrubbed	_
57-8	10195-10196	,	_
57-9	10197-10202	where	_
57-10	10203-10206	TRs	_
57-11	10207-10211	with	_
57-12	10212-10213	a	_
57-13	10214-10219	frame	_
57-14	10220-10224	wise	_
57-15	10225-10237	displacement	_
57-16	10238-10239	>	_
57-17	10240-10243	0.9	_
57-18	10244-10248	were	_
57-19	10249-10256	removed	_
57-20	10257-10258	,	_
57-21	10259-10261	as	_
57-22	10262-10272	previously	_
57-23	10273-10284	recommended	_
57-24	10285-10286	.	_

Text=Image processing and statistical analyses were conducted using statistical parametric mapping methods as implemented in FMRI Expert Analysis Tool (FEAT, Version 5.98, part of FMRIB ’ s Software Library, www.fmrib.ox.ac.uk/fsl).
58-1	10287-10292	Image	_
58-2	10293-10303	processing	_
58-3	10304-10307	and	_
58-4	10308-10319	statistical	_
58-5	10320-10328	analyses	_
58-6	10329-10333	were	_
58-7	10334-10343	conducted	_
58-8	10344-10349	using	_
58-9	10350-10361	statistical	_
58-10	10362-10372	parametric	_
58-11	10373-10380	mapping	_
58-12	10381-10388	methods	_
58-13	10389-10391	as	_
58-14	10392-10403	implemented	_
58-15	10404-10406	in	_
58-16	10407-10411	FMRI	_
58-17	10412-10418	Expert	_
58-18	10419-10427	Analysis	_
58-19	10428-10432	Tool	_
58-20	10433-10434	(	_
58-21	10435-10439	FEAT	_
58-22	10440-10441	,	_
58-23	10442-10449	Version	_
58-24	10450-10454	5.98	_
58-25	10455-10456	,	_
58-26	10457-10461	part	_
58-27	10462-10464	of	_
58-28	10465-10470	FMRIB	_
58-29	10471-10472	’	_
58-30	10473-10474	s	_
58-31	10475-10483	Software	_
58-32	10484-10491	Library	_
58-33	10492-10493	,	_
58-34	10494-10516	www.fmrib.ox.ac.uk/fsl	_
58-35	10517-10518	)	_
58-36	10519-10520	.	_

Text=The following prestatistics processing was applied; motion correction using MCFLIRT; slice-timing correction using Fourier-space time-series phase-shifting; nonbrain removal using BET (Brain Extraction Tool) spatial smoothing using a Gaussian kernel of FWHM 5 mm; grand-mean intensity normalization of the entire 4D data set by a single multiplicative factor; high-pass temporal filtering (Gaussian-weighted least-squares straight line fitting, with sigma = 50.0 s).
59-1	10521-10524	The	_
59-2	10525-10534	following	_
59-3	10535-10548	prestatistics	_
59-4	10549-10559	processing	_
59-5	10560-10563	was	_
59-6	10564-10571	applied	_
59-7	10572-10573	;	_
59-8	10574-10580	motion	_
59-9	10581-10591	correction	_
59-10	10592-10597	using	_
59-11	10598-10605	MCFLIRT	_
59-12	10606-10607	;	_
59-13	10608-10620	slice-timing	_
59-14	10621-10631	correction	_
59-15	10632-10637	using	_
59-16	10638-10651	Fourier-space	_
59-17	10652-10663	time-series	_
59-18	10664-10678	phase-shifting	_
59-19	10679-10680	;	_
59-20	10681-10689	nonbrain	_
59-21	10690-10697	removal	_
59-22	10698-10703	using	_
59-23	10704-10707	BET	_
59-24	10708-10709	(	_
59-25	10710-10715	Brain	_
59-26	10716-10726	Extraction	_
59-27	10727-10731	Tool	_
59-28	10732-10733	)	_
59-29	10734-10741	spatial	_
59-30	10742-10751	smoothing	_
59-31	10752-10757	using	_
59-32	10758-10759	a	_
59-33	10760-10768	Gaussian	_
59-34	10769-10775	kernel	_
59-35	10776-10778	of	_
59-36	10779-10783	FWHM	_
59-37	10784-10785	5	_
59-38	10786-10788	mm	_
59-39	10789-10790	;	_
59-40	10791-10801	grand-mean	_
59-41	10802-10811	intensity	_
59-42	10812-10825	normalization	_
59-43	10826-10828	of	_
59-44	10829-10832	the	_
59-45	10833-10839	entire	_
59-46	10840-10842	4D	_
59-47	10843-10847	data	_
59-48	10848-10851	set	_
59-49	10852-10854	by	_
59-50	10855-10856	a	_
59-51	10857-10863	single	_
59-52	10864-10878	multiplicative	_
59-53	10879-10885	factor	_
59-54	10886-10887	;	_
59-55	10888-10897	high-pass	_
59-56	10898-10906	temporal	_
59-57	10907-10916	filtering	_
59-58	10917-10918	(	_
59-59	10919-10936	Gaussian-weighted	_
59-60	10937-10950	least-squares	_
59-61	10951-10959	straight	_
59-62	10960-10964	line	_
59-63	10965-10972	fitting	_
59-64	10973-10974	,	_
59-65	10975-10979	with	_
59-66	10980-10985	sigma	_
59-67	10986-10987	=	_
59-68	10988-10992	50.0	_
59-69	10993-10994	s	_
59-70	10995-10996	)	_
59-71	10997-10998	.	_

Text=Registration to high resolution structural (single subject general linear model [GLM]) and standard space (group-level GLM) images was carried out using FLIRT.
60-1	10999-11011	Registration	_
60-2	11012-11014	to	_
60-3	11015-11019	high	_
60-4	11020-11030	resolution	_
60-5	11031-11041	structural	_
60-6	11042-11043	(	_
60-7	11044-11050	single	_
60-8	11051-11058	subject	_
60-9	11059-11066	general	_
60-10	11067-11073	linear	_
60-11	11074-11079	model	_
60-12	11080-11081	[	_
60-13	11082-11085	GLM	_
60-14	11086-11087	]	_
60-15	11088-11089	)	_
60-16	11090-11093	and	_
60-17	11094-11102	standard	_
60-18	11103-11108	space	_
60-19	11109-11110	(	_
60-20	11111-11122	group-level	_
60-21	11123-11126	GLM	_
60-22	11127-11128	)	_
60-23	11129-11135	images	_
60-24	11136-11139	was	_
60-25	11140-11147	carried	_
60-26	11148-11151	out	_
60-27	11152-11157	using	_
60-28	11158-11163	FLIRT	_
60-29	11164-11165	.	_

Text=Time-series analysis was carried out using FMRIB ’ s Improved Linear Model (FILM) with local autocorrelation correction.
61-1	11166-11177	Time-series	_
61-2	11178-11186	analysis	_
61-3	11187-11190	was	_
61-4	11191-11198	carried	_
61-5	11199-11202	out	_
61-6	11203-11208	using	_
61-7	11209-11214	FMRIB	_
61-8	11215-11216	’	_
61-9	11217-11218	s	_
61-10	11219-11227	Improved	_
61-11	11228-11234	Linear	_
61-12	11235-11240	Model	_
61-13	11241-11242	(	_
61-14	11243-11247	FILM	_
61-15	11248-11249	)	_
61-16	11250-11254	with	_
61-17	11255-11260	local	_
61-18	11261-11276	autocorrelation	_
61-19	11277-11287	correction	_
61-20	11288-11289	.	_

Text=To further correct for any potential movement confounds, motion regressors were estimated via MCFLIRT and scrubbed TRs were added as covariates of no interest to each individual design matrix.
62-1	11290-11292	To	_
62-2	11293-11300	further	_
62-3	11301-11308	correct	_
62-4	11309-11312	for	_
62-5	11313-11316	any	_
62-6	11317-11326	potential	_
62-7	11327-11335	movement	_
62-8	11336-11345	confounds	_
62-9	11346-11347	,	_
62-10	11348-11354	motion	_
62-11	11355-11365	regressors	_
62-12	11366-11370	were	_
62-13	11371-11380	estimated	_
62-14	11381-11384	via	_
62-15	11385-11392	MCFLIRT	_
62-16	11393-11396	and	_
62-17	11397-11405	scrubbed	_
62-18	11406-11409	TRs	_
62-19	11410-11414	were	_
62-20	11415-11420	added	_
62-21	11421-11423	as	_
62-22	11424-11434	covariates	_
62-23	11435-11437	of	_
62-24	11438-11440	no	_
62-25	11441-11449	interest	_
62-26	11450-11452	to	_
62-27	11453-11457	each	_
62-28	11458-11468	individual	_
62-29	11469-11475	design	_
62-30	11476-11482	matrix	_
62-31	11483-11484	.	_

Text=After quality control procedures, 183 individuals out of the 197 (89 low SCZ-RPS and 94 high SCZ-RPS) where included in the reversal learning analysis.
63-1	11485-11490	After	_
63-2	11491-11498	quality	_
63-3	11499-11506	control	_
63-4	11507-11517	procedures	_
63-5	11518-11519	,	_
63-6	11520-11523	183	_
63-7	11524-11535	individuals	_
63-8	11536-11539	out	_
63-9	11540-11542	of	_
63-10	11543-11546	the	_
63-11	11547-11550	197	_
63-12	11551-11552	(	_
63-13	11553-11555	89	_
63-14	11556-11559	low	_
63-15	11560-11567	SCZ-RPS	_
63-16	11568-11571	and	_
63-17	11572-11574	94	_
63-18	11575-11579	high	_
63-19	11580-11587	SCZ-RPS	_
63-20	11588-11589	)	_
63-21	11590-11595	where	_
63-22	11596-11604	included	_
63-23	11605-11607	in	_
63-24	11608-11611	the	_
63-25	11612-11620	reversal	_
63-26	11621-11629	learning	_
63-27	11630-11638	analysis	_
63-28	11639-11640	.	_

Text=Functional Imaging Paradigm: Reversal Learning Participants learned to choose 1 of 2 simultaneously presented colors (“ blue ” and “ green ”) by receiving monetary reward for correct choices and monetary punishment for wrong choices (eg, +1 pence [p] for “ blue ” and −1p for “ green ”).
64-1	11641-11651	Functional	_
64-2	11652-11659	Imaging	_
64-3	11660-11668	Paradigm	_
64-4	11669-11670	:	_
64-5	11671-11679	Reversal	_
64-6	11680-11688	Learning	_
64-7	11689-11701	Participants	_
64-8	11702-11709	learned	_
64-9	11710-11712	to	_
64-10	11713-11719	choose	_
64-11	11720-11721	1	_
64-12	11722-11724	of	_
64-13	11725-11726	2	_
64-14	11727-11741	simultaneously	_
64-15	11742-11751	presented	_
64-16	11752-11758	colors	_
64-17	11759-11760	(	_
64-18	11761-11762	“	_
64-19	11763-11767	blue	_
64-20	11768-11769	”	_
64-21	11770-11773	and	_
64-22	11774-11775	“	_
64-23	11776-11781	green	_
64-24	11782-11783	”	_
64-25	11784-11785	)	_
64-26	11786-11788	by	_
64-27	11789-11798	receiving	_
64-28	11799-11807	monetary	_
64-29	11808-11814	reward	_
64-30	11815-11818	for	_
64-31	11819-11826	correct	_
64-32	11827-11834	choices	_
64-33	11835-11838	and	_
64-34	11839-11847	monetary	_
64-35	11848-11858	punishment	_
64-36	11859-11862	for	_
64-37	11863-11868	wrong	_
64-38	11869-11876	choices	_
64-39	11877-11878	(	_
64-40	11879-11881	eg	_
64-41	11882-11883	,	_
64-42	11884-11886	+1	_
64-43	11887-11892	pence	_
64-44	11893-11894	[	_
64-45	11895-11896	p	_
64-46	11897-11898	]	_
64-47	11899-11902	for	_
64-48	11903-11904	“	_
64-49	11905-11909	blue	_
64-50	11910-11911	”	_
64-51	11912-11915	and	_
64-52	11916-11919	−1p	_
64-53	11920-11923	for	_
64-54	11924-11925	“	_
64-55	11926-11931	green	_
64-56	11932-11933	”	_
64-57	11934-11935	)	_
64-58	11936-11937	.	_

Text=After 7–11 trials, reward/punishment contingencies were reversed so that the previously rewarded color was now punished and vice versa.
65-1	11938-11943	After	_
65-2	11944-11948	7–11	_
65-3	11949-11955	trials	_
65-4	11956-11957	,	_
65-5	11958-11975	reward/punishment	_
65-6	11976-11989	contingencies	_
65-7	11990-11994	were	_
65-8	11995-12003	reversed	_
65-9	12004-12006	so	_
65-10	12007-12011	that	_
65-11	12012-12015	the	_
65-12	12016-12026	previously	_
65-13	12027-12035	rewarded	_
65-14	12036-12041	color	_
65-15	12042-12045	was	_
65-16	12046-12049	now	_
65-17	12050-12058	punished	_
65-18	12059-12062	and	_
65-19	12063-12067	vice	_
65-20	12068-12073	versa	_
65-21	12074-12075	.	_

Text=Participants were instructed to maximize their earnings during the learning session, which consisted of 12 reversal episodes in total (108 choice trials).
66-1	12076-12088	Participants	_
66-2	12089-12093	were	_
66-3	12094-12104	instructed	_
66-4	12105-12107	to	_
66-5	12108-12116	maximize	_
66-6	12117-12122	their	_
66-7	12123-12131	earnings	_
66-8	12132-12138	during	_
66-9	12139-12142	the	_
66-10	12143-12151	learning	_
66-11	12152-12159	session	_
66-12	12160-12161	,	_
66-13	12162-12167	which	_
66-14	12168-12177	consisted	_
66-15	12178-12180	of	_
66-16	12181-12183	12	_
66-17	12184-12192	reversal	_
66-18	12193-12201	episodes	_
66-19	12202-12204	in	_
66-20	12205-12210	total	_
66-21	12211-12212	(	_
66-22	12213-12216	108	_
66-23	12217-12223	choice	_
66-24	12224-12230	trials	_
66-25	12231-12232	)	_
66-26	12233-12234	.	_

Text=Within each reversal episode we included either 1 or 2 PE (probabilistic error) trials, in which “ wrong ” -feedback was given for correct choices, even though the reward contingencies had not changed.
67-1	12235-12241	Within	_
67-2	12242-12246	each	_
67-3	12247-12255	reversal	_
67-4	12256-12263	episode	_
67-5	12264-12266	we	_
67-6	12267-12275	included	_
67-7	12276-12282	either	_
67-8	12283-12284	1	_
67-9	12285-12287	or	_
67-10	12288-12289	2	_
67-11	12290-12292	PE	_
67-12	12293-12294	(	_
67-13	12295-12308	probabilistic	_
67-14	12309-12314	error	_
67-15	12315-12316	)	_
67-16	12317-12323	trials	_
67-17	12324-12325	,	_
67-18	12326-12328	in	_
67-19	12329-12334	which	_
67-20	12335-12336	“	_
67-21	12337-12342	wrong	_
67-22	12343-12344	”	_
67-23	12345-12354	-feedback	_
67-24	12355-12358	was	_
67-25	12359-12364	given	_
67-26	12365-12368	for	_
67-27	12369-12376	correct	_
67-28	12377-12384	choices	_
67-29	12385-12386	,	_
67-30	12387-12391	even	_
67-31	12392-12398	though	_
67-32	12399-12402	the	_
67-33	12403-12409	reward	_
67-34	12410-12423	contingencies	_
67-35	12424-12427	had	_
67-36	12428-12431	not	_
67-37	12432-12439	changed	_
67-38	12440-12441	.	_

Text=At the start of each choice trial, participants were presented with a response cue consisting of 2 white frames surrounding the colors and prompting the participants to press the left or right button on a response box to choose one color.
68-1	12442-12444	At	_
68-2	12445-12448	the	_
68-3	12449-12454	start	_
68-4	12455-12457	of	_
68-5	12458-12462	each	_
68-6	12463-12469	choice	_
68-7	12470-12475	trial	_
68-8	12476-12477	,	_
68-9	12478-12490	participants	_
68-10	12491-12495	were	_
68-11	12496-12505	presented	_
68-12	12506-12510	with	_
68-13	12511-12512	a	_
68-14	12513-12521	response	_
68-15	12522-12525	cue	_
68-16	12526-12536	consisting	_
68-17	12537-12539	of	_
68-18	12540-12541	2	_
68-19	12542-12547	white	_
68-20	12548-12554	frames	_
68-21	12555-12566	surrounding	_
68-22	12567-12570	the	_
68-23	12571-12577	colors	_
68-24	12578-12581	and	_
68-25	12582-12591	prompting	_
68-26	12592-12595	the	_
68-27	12596-12608	participants	_
68-28	12609-12611	to	_
68-29	12612-12617	press	_
68-30	12618-12621	the	_
68-31	12622-12626	left	_
68-32	12627-12629	or	_
68-33	12630-12635	right	_
68-34	12636-12642	button	_
68-35	12643-12645	on	_
68-36	12646-12647	a	_
68-37	12648-12656	response	_
68-38	12657-12660	box	_
68-39	12661-12663	to	_
68-40	12664-12670	choose	_
68-41	12671-12674	one	_
68-42	12675-12680	color	_
68-43	12681-12682	.	_

Text=Response feedback (choice outcome) was given subsequently using a centrally presented white “ smiley ” (correct choice) or red “ frowny ” (incorrect choice) face and an earnings counter changing incrementally by ±1p.
69-1	12683-12691	Response	_
69-2	12692-12700	feedback	_
69-3	12701-12702	(	_
69-4	12703-12709	choice	_
69-5	12710-12717	outcome	_
69-6	12718-12719	)	_
69-7	12720-12723	was	_
69-8	12724-12729	given	_
69-9	12730-12742	subsequently	_
69-10	12743-12748	using	_
69-11	12749-12750	a	_
69-12	12751-12760	centrally	_
69-13	12761-12770	presented	_
69-14	12771-12776	white	_
69-15	12777-12778	“	_
69-16	12779-12785	smiley	_
69-17	12786-12787	”	_
69-18	12788-12789	(	_
69-19	12790-12797	correct	_
69-20	12798-12804	choice	_
69-21	12805-12806	)	_
69-22	12807-12809	or	_
69-23	12810-12813	red	_
69-24	12814-12815	“	_
69-25	12816-12822	frowny	_
69-26	12823-12824	”	_
69-27	12825-12826	(	_
69-28	12827-12836	incorrect	_
69-29	12837-12843	choice	_
69-30	12844-12845	)	_
69-31	12846-12850	face	_
69-32	12851-12854	and	_
69-33	12855-12857	an	_
69-34	12858-12866	earnings	_
69-35	12867-12874	counter	_
69-36	12875-12883	changing	_
69-37	12884-12897	incrementally	_
69-38	12898-12900	by	_
69-39	12901-12904	±1p	_
69-40	12905-12906	.	_

Text=In trials following reversal or PE events, ie, in those trials used for fMRI analysis, response cues and feedback stimuli were presented with a jittered duration (cue: 4–8 s, mean 5.5 s; feedback: 0.75 s followed by 3–7 s [mean 4.5 s] inter-trial-interval [ITI]: paradigm schematic in supplementary figure S2).
70-1	12907-12909	In	_
70-2	12910-12916	trials	_
70-3	12917-12926	following	_
70-4	12927-12935	reversal	_
70-5	12936-12938	or	_
70-6	12939-12941	PE	_
70-7	12942-12948	events	_
70-8	12949-12950	,	_
70-9	12951-12953	ie	_
70-10	12954-12955	,	_
70-11	12956-12958	in	_
70-12	12959-12964	those	_
70-13	12965-12971	trials	_
70-14	12972-12976	used	_
70-15	12977-12980	for	_
70-16	12981-12985	fMRI	_
70-17	12986-12994	analysis	_
70-18	12995-12996	,	_
70-19	12997-13005	response	_
70-20	13006-13010	cues	_
70-21	13011-13014	and	_
70-22	13015-13023	feedback	_
70-23	13024-13031	stimuli	_
70-24	13032-13036	were	_
70-25	13037-13046	presented	_
70-26	13047-13051	with	_
70-27	13052-13053	a	_
70-28	13054-13062	jittered	_
70-29	13063-13071	duration	_
70-30	13072-13073	(	_
70-31	13074-13077	cue	_
70-32	13078-13079	:	_
70-33	13080-13083	4–8	_
70-34	13084-13085	s	_
70-35	13086-13087	,	_
70-36	13088-13092	mean	_
70-37	13093-13096	5.5	_
70-38	13097-13098	s	_
70-39	13099-13100	;	_
70-40	13101-13109	feedback	_
70-41	13110-13111	:	_
70-42	13112-13116	0.75	_
70-43	13117-13118	s	_
70-44	13119-13127	followed	_
70-45	13128-13130	by	_
70-46	13131-13134	3–7	_
70-47	13135-13136	s	_
70-48	13137-13138	[	_
70-49	13139-13143	mean	_
70-50	13144-13147	4.5	_
70-51	13148-13149	s	_
70-52	13150-13151	]	_
70-53	13152-13172	inter-trial-interval	_
70-54	13173-13174	[	_
70-55	13175-13178	ITI	_
70-56	13179-13180	]	_
70-57	13181-13182	:	_
70-58	13183-13191	paradigm	_
70-59	13192-13201	schematic	_
70-60	13202-13204	in	_
70-61	13205-13218	supplementary	_
70-62	13219-13225	figure	_
70-63	13226-13228	S2	_
70-64	13229-13230	)	_
70-65	13231-13232	.	_

Text=To reduce scanning time, in all other (standard) trials we used fixed and shorter stimulus durations (cue: 2 s, feedback: 0.75 s).
71-1	13233-13235	To	_
71-2	13236-13242	reduce	_
71-3	13243-13251	scanning	_
71-4	13252-13256	time	_
71-5	13257-13258	,	_
71-6	13259-13261	in	_
71-7	13262-13265	all	_
71-8	13266-13271	other	_
71-9	13272-13273	(	_
71-10	13274-13282	standard	_
71-11	13283-13284	)	_
71-12	13285-13291	trials	_
71-13	13292-13294	we	_
71-14	13295-13299	used	_
71-15	13300-13305	fixed	_
71-16	13306-13309	and	_
71-17	13310-13317	shorter	_
71-18	13318-13326	stimulus	_
71-19	13327-13336	durations	_
71-20	13337-13338	(	_
71-21	13339-13342	cue	_
71-22	13343-13344	:	_
71-23	13345-13346	2	_
71-24	13347-13348	s	_
71-25	13349-13350	,	_
71-26	13351-13359	feedback	_
71-27	13360-13361	:	_
71-28	13362-13366	0.75	_
71-29	13367-13368	s	_
71-30	13369-13370	)	_
71-31	13371-13372	.	_

Text=ITIs showed the 2 colors without response cue or feedback and were 0.5 s long after standard trials and between 4 and 8 s (mean 5.5 s) after PEs and reversals.
72-1	13373-13377	ITIs	_
72-2	13378-13384	showed	_
72-3	13385-13388	the	_
72-4	13389-13390	2	_
72-5	13391-13397	colors	_
72-6	13398-13405	without	_
72-7	13406-13414	response	_
72-8	13415-13418	cue	_
72-9	13419-13421	or	_
72-10	13422-13430	feedback	_
72-11	13431-13434	and	_
72-12	13435-13439	were	_
72-13	13440-13443	0.5	_
72-14	13444-13445	s	_
72-15	13446-13450	long	_
72-16	13451-13456	after	_
72-17	13457-13465	standard	_
72-18	13466-13472	trials	_
72-19	13473-13476	and	_
72-20	13477-13484	between	_
72-21	13485-13486	4	_
72-22	13487-13490	and	_
72-23	13491-13492	8	_
72-24	13493-13494	s	_
72-25	13495-13496	(	_
72-26	13497-13501	mean	_
72-27	13502-13505	5.5	_
72-28	13506-13507	s	_
72-29	13508-13509	)	_
72-30	13510-13515	after	_
72-31	13516-13519	PEs	_
72-32	13520-13523	and	_
72-33	13524-13533	reversals	_
72-34	13534-13535	.	_

Text=BOLD response analysis focused on brain activation differences as a function choice behavior (switch> stay response) or choice outcomes (reward> punishment) in post-PE and postreversal trials.
73-1	13536-13540	BOLD	_
73-2	13541-13549	response	_
73-3	13550-13558	analysis	_
73-4	13559-13566	focused	_
73-5	13567-13569	on	_
73-6	13570-13575	brain	_
73-7	13576-13586	activation	_
73-8	13587-13598	differences	_
73-9	13599-13601	as	_
73-10	13602-13603	a	_
73-11	13604-13612	function	_
73-12	13613-13619	choice	_
73-13	13620-13628	behavior	_
73-14	13629-13630	(	_
73-15	13631-13637	switch	_
73-16	13638-13639	>	_
73-17	13640-13644	stay	_
73-18	13645-13653	response	_
73-19	13654-13655	)	_
73-20	13656-13658	or	_
73-21	13659-13665	choice	_
73-22	13666-13674	outcomes	_
73-23	13675-13676	(	_
73-24	13677-13683	reward	_
73-25	13684-13685	>	_
73-26	13686-13696	punishment	_
73-27	13697-13698	)	_
73-28	13699-13701	in	_
73-29	13702-13709	post-PE	_
73-30	13710-13713	and	_
73-31	13714-13726	postreversal	_
73-32	13727-13733	trials	_
73-33	13734-13735	.	_

Text=We selected those trials for analysis as they yielded a comparatively balanced number of rewards/and punishments (correct/vs incorrect choices) compared to standard trials (which were disproportionally more rewarded than punished.
74-1	13736-13738	We	_
74-2	13739-13747	selected	_
74-3	13748-13753	those	_
74-4	13754-13760	trials	_
74-5	13761-13764	for	_
74-6	13765-13773	analysis	_
74-7	13774-13776	as	_
74-8	13777-13781	they	_
74-9	13782-13789	yielded	_
74-10	13790-13791	a	_
74-11	13792-13805	comparatively	_
74-12	13806-13814	balanced	_
74-13	13815-13821	number	_
74-14	13822-13824	of	_
74-15	13825-13836	rewards/and	_
74-16	13837-13848	punishments	_
74-17	13849-13850	(	_
74-18	13851-13861	correct/vs	_
74-19	13862-13871	incorrect	_
74-20	13872-13879	choices	_
74-21	13880-13881	)	_
74-22	13882-13890	compared	_
74-23	13891-13893	to	_
74-24	13894-13902	standard	_
74-25	13903-13909	trials	_
74-26	13910-13911	(	_
74-27	13912-13917	which	_
74-28	13918-13922	were	_
74-29	13923-13940	disproportionally	_
74-30	13941-13945	more	_
74-31	13946-13954	rewarded	_
74-32	13955-13959	than	_
74-33	13960-13968	punished	_
74-34	13969-13970	.	_

Text=These regressors were modeled BOLD during decisional processes under high levels of uncertainty, ie, after participants had to choose a stay or switch strategy in response to an unexpected punishment in the previous (PE or reversal) trial and during rewarding or punishment based feedback.
75-1	13971-13976	These	_
75-2	13977-13987	regressors	_
75-3	13988-13992	were	_
75-4	13993-14000	modeled	_
75-5	14001-14005	BOLD	_
75-6	14006-14012	during	_
75-7	14013-14023	decisional	_
75-8	14024-14033	processes	_
75-9	14034-14039	under	_
75-10	14040-14044	high	_
75-11	14045-14051	levels	_
75-12	14052-14054	of	_
75-13	14055-14066	uncertainty	_
75-14	14067-14068	,	_
75-15	14069-14071	ie	_
75-16	14072-14073	,	_
75-17	14074-14079	after	_
75-18	14080-14092	participants	_
75-19	14093-14096	had	_
75-20	14097-14099	to	_
75-21	14100-14106	choose	_
75-22	14107-14108	a	_
75-23	14109-14113	stay	_
75-24	14114-14116	or	_
75-25	14117-14123	switch	_
75-26	14124-14132	strategy	_
75-27	14133-14135	in	_
75-28	14136-14144	response	_
75-29	14145-14147	to	_
75-30	14148-14150	an	_
75-31	14151-14161	unexpected	_
75-32	14162-14172	punishment	_
75-33	14173-14175	in	_
75-34	14176-14179	the	_
75-35	14180-14188	previous	_
75-36	14189-14190	(	_
75-37	14191-14193	PE	_
75-38	14194-14196	or	_
75-39	14197-14205	reversal	_
75-40	14206-14207	)	_
75-41	14208-14213	trial	_
75-42	14214-14217	and	_
75-43	14218-14224	during	_
75-44	14225-14234	rewarding	_
75-45	14235-14237	or	_
75-46	14238-14248	punishment	_
75-47	14249-14254	based	_
75-48	14255-14263	feedback	_
75-49	14264-14265	.	_

Text=BOLD signal changes were regressed by task predictor functions (switch> stay and reward> punishment) convolved with a canonical hemodynamic response function.
76-1	14266-14270	BOLD	_
76-2	14271-14277	signal	_
76-3	14278-14285	changes	_
76-4	14286-14290	were	_
76-5	14291-14300	regressed	_
76-6	14301-14303	by	_
76-7	14304-14308	task	_
76-8	14309-14318	predictor	_
76-9	14319-14328	functions	_
76-10	14329-14330	(	_
76-11	14331-14337	switch	_
76-12	14338-14339	>	_
76-13	14340-14344	stay	_
76-14	14345-14348	and	_
76-15	14349-14355	reward	_
76-16	14356-14357	>	_
76-17	14358-14368	punishment	_
76-18	14369-14370	)	_
76-19	14371-14380	convolved	_
76-20	14381-14385	with	_
76-21	14386-14387	a	_
76-22	14388-14397	canonical	_
76-23	14398-14409	hemodynamic	_
76-24	14410-14418	response	_
76-25	14419-14427	function	_
76-26	14428-14429	.	_

Text=For the switch-stay contrast, predictor functions were synchronized with the onset of the response cue in post-PE/-reversal trials; having a duration of 4000 ms and including both predecisional and response processing.
77-1	14430-14433	For	_
77-2	14434-14437	the	_
77-3	14438-14449	switch-stay	_
77-4	14450-14458	contrast	_
77-5	14459-14460	,	_
77-6	14461-14470	predictor	_
77-7	14471-14480	functions	_
77-8	14481-14485	were	_
77-9	14486-14498	synchronized	_
77-10	14499-14503	with	_
77-11	14504-14507	the	_
77-12	14508-14513	onset	_
77-13	14514-14516	of	_
77-14	14517-14520	the	_
77-15	14521-14529	response	_
77-16	14530-14533	cue	_
77-17	14534-14536	in	_
77-18	14537-14554	post-PE/-reversal	_
77-19	14555-14561	trials	_
77-20	14562-14563	;	_
77-21	14564-14570	having	_
77-22	14571-14572	a	_
77-23	14573-14581	duration	_
77-24	14582-14584	of	_
77-25	14585-14589	4000	_
77-26	14590-14592	ms	_
77-27	14593-14596	and	_
77-28	14597-14606	including	_
77-29	14607-14611	both	_
77-30	14612-14625	predecisional	_
77-31	14626-14629	and	_
77-32	14630-14638	response	_
77-33	14639-14649	processing	_
77-34	14650-14651	.	_

Text=For the reward-punishment contrast and predictor time courses were locked to the onset of feedback stimuli in post-PE and postreversal trials, with a fixed duration of 3750 ms, which corresponded to the earliest possible start of the next choice trial.
78-1	14652-14655	For	_
78-2	14656-14659	the	_
78-3	14660-14677	reward-punishment	_
78-4	14678-14686	contrast	_
78-5	14687-14690	and	_
78-6	14691-14700	predictor	_
78-7	14701-14705	time	_
78-8	14706-14713	courses	_
78-9	14714-14718	were	_
78-10	14719-14725	locked	_
78-11	14726-14728	to	_
78-12	14729-14732	the	_
78-13	14733-14738	onset	_
78-14	14739-14741	of	_
78-15	14742-14750	feedback	_
78-16	14751-14758	stimuli	_
78-17	14759-14761	in	_
78-18	14762-14769	post-PE	_
78-19	14770-14773	and	_
78-20	14774-14786	postreversal	_
78-21	14787-14793	trials	_
78-22	14794-14795	,	_
78-23	14796-14800	with	_
78-24	14801-14802	a	_
78-25	14803-14808	fixed	_
78-26	14809-14817	duration	_
78-27	14818-14820	of	_
78-28	14821-14825	3750	_
78-29	14826-14828	ms	_
78-30	14829-14830	,	_
78-31	14831-14836	which	_
78-32	14837-14849	corresponded	_
78-33	14850-14852	to	_
78-34	14853-14856	the	_
78-35	14857-14865	earliest	_
78-36	14866-14874	possible	_
78-37	14875-14880	start	_
78-38	14881-14883	of	_
78-39	14884-14887	the	_
78-40	14888-14892	next	_
78-41	14893-14899	choice	_
78-42	14900-14905	trial	_
78-43	14906-14907	.	_

Text=For each subject, statistical contrast images reward> punishment and switch> stay were obtained, which have previously shown good test–retest reliability.
79-1	14908-14911	For	_
79-2	14912-14916	each	_
79-3	14917-14924	subject	_
79-4	14925-14926	,	_
79-5	14927-14938	statistical	_
79-6	14939-14947	contrast	_
79-7	14948-14954	images	_
79-8	14955-14961	reward	_
79-9	14962-14963	>	_
79-10	14964-14974	punishment	_
79-11	14975-14978	and	_
79-12	14979-14985	switch	_
79-13	14986-14987	>	_
79-14	14988-14992	stay	_
79-15	14993-14997	were	_
79-16	14998-15006	obtained	_
79-17	15007-15008	,	_
79-18	15009-15014	which	_
79-19	15015-15019	have	_
79-20	15020-15030	previously	_
79-21	15031-15036	shown	_
79-22	15037-15041	good	_
79-23	15042-15053	test–retest	_
79-24	15054-15065	reliability	_
79-25	15066-15067	.	_

Text=Group level analysis was carried out using FLAME (FMRIB ’ s Local Analysis of Mixed Effects).
80-1	15068-15073	Group	_
80-2	15074-15079	level	_
80-3	15080-15088	analysis	_
80-4	15089-15092	was	_
80-5	15093-15100	carried	_
80-6	15101-15104	out	_
80-7	15105-15110	using	_
80-8	15111-15116	FLAME	_
80-9	15117-15118	(	_
80-10	15119-15124	FMRIB	_
80-11	15125-15126	’	_
80-12	15127-15128	s	_
80-13	15129-15134	Local	_
80-14	15135-15143	Analysis	_
80-15	15144-15146	of	_
80-16	15147-15152	Mixed	_
80-17	15153-15160	Effects	_
80-18	15161-15162	)	_
80-19	15163-15164	.	_

Text=We explored the (1) group level contrasts (1-sample t-tests) and (2) SCZ-RPS group effects (2-sample t-tests) across (a) the whole brain, (b) within the ventral striatum (VS) region of interest, defined as the bilateral accumbens in the Harvard-Oxford Subcortical Structural Atlas, based on our previous observations between VS BOLD and SCZ-RPS, and (c) a preinvestigated reward network.
81-1	15165-15167	We	_
81-2	15168-15176	explored	_
81-3	15177-15180	the	_
81-4	15181-15182	(	_
81-5	15183-15184	1	_
81-6	15185-15186	)	_
81-7	15187-15192	group	_
81-8	15193-15198	level	_
81-9	15199-15208	contrasts	_
81-10	15209-15210	(	_
81-11	15211-15219	1-sample	_
81-12	15220-15227	t-tests	_
81-13	15228-15229	)	_
81-14	15230-15233	and	_
81-15	15234-15235	(	_
81-16	15236-15237	2	_
81-17	15238-15239	)	_
81-18	15240-15247	SCZ-RPS	_
81-19	15248-15253	group	_
81-20	15254-15261	effects	_
81-21	15262-15263	(	_
81-22	15264-15272	2-sample	_
81-23	15273-15280	t-tests	_
81-24	15281-15282	)	_
81-25	15283-15289	across	_
81-26	15290-15291	(	_
81-27	15292-15293	a	_
81-28	15294-15295	)	_
81-29	15296-15299	the	_
81-30	15300-15305	whole	_
81-31	15306-15311	brain	_
81-32	15312-15313	,	_
81-33	15314-15315	(	_
81-34	15316-15317	b	_
81-35	15318-15319	)	_
81-36	15320-15326	within	_
81-37	15327-15330	the	_
81-38	15331-15338	ventral	_
81-39	15339-15347	striatum	_
81-40	15348-15349	(	_
81-41	15350-15352	VS	_
81-42	15353-15354	)	_
81-43	15355-15361	region	_
81-44	15362-15364	of	_
81-45	15365-15373	interest	_
81-46	15374-15375	,	_
81-47	15376-15383	defined	_
81-48	15384-15386	as	_
81-49	15387-15390	the	_
81-50	15391-15400	bilateral	_
81-51	15401-15410	accumbens	_
81-52	15411-15413	in	_
81-53	15414-15417	the	_
81-54	15418-15432	Harvard-Oxford	_
81-55	15433-15444	Subcortical	_
81-56	15445-15455	Structural	_
81-57	15456-15461	Atlas	_
81-58	15462-15463	,	_
81-59	15464-15469	based	_
81-60	15470-15472	on	_
81-61	15473-15476	our	_
81-62	15477-15485	previous	_
81-63	15486-15498	observations	_
81-64	15499-15506	between	_
81-65	15507-15509	VS	_
81-66	15510-15514	BOLD	_
81-67	15515-15518	and	_
81-68	15519-15526	SCZ-RPS	_
81-69	15527-15528	,	_
81-70	15529-15532	and	_
81-71	15533-15534	(	_
81-72	15535-15536	c	_
81-73	15537-15538	)	_
81-74	15539-15540	a	_
81-75	15541-15556	preinvestigated	_
81-76	15557-15563	reward	_
81-77	15564-15571	network	_
81-78	15572-15573	.	_

Text=For whole group analysis (1-sample t-tests) the family wise error (FWE) was controlled by estimating the minimum Z intensity using fsl ’ s “ ptoz ” function and contrast smoothness parameters, where Z> 4.2 controlled for the FWE across both choice decision and outcome.
82-1	15574-15577	For	_
82-2	15578-15583	whole	_
82-3	15584-15589	group	_
82-4	15590-15598	analysis	_
82-5	15599-15600	(	_
82-6	15601-15609	1-sample	_
82-7	15610-15617	t-tests	_
82-8	15618-15619	)	_
82-9	15620-15623	the	_
82-10	15624-15630	family	_
82-11	15631-15635	wise	_
82-12	15636-15641	error	_
82-13	15642-15643	(	_
82-14	15644-15647	FWE	_
82-15	15648-15649	)	_
82-16	15650-15653	was	_
82-17	15654-15664	controlled	_
82-18	15665-15667	by	_
82-19	15668-15678	estimating	_
82-20	15679-15682	the	_
82-21	15683-15690	minimum	_
82-22	15691-15692	Z	_
82-23	15693-15702	intensity	_
82-24	15703-15708	using	_
82-25	15709-15712	fsl	_
82-26	15713-15714	’	_
82-27	15715-15716	s	_
82-28	15717-15718	“	_
82-29	15719-15723	ptoz	_
82-30	15724-15725	”	_
82-31	15726-15734	function	_
82-32	15735-15738	and	_
82-33	15739-15747	contrast	_
82-34	15748-15758	smoothness	_
82-35	15759-15769	parameters	_
82-36	15770-15771	,	_
82-37	15772-15777	where	_
82-38	15778-15779	Z	_
82-39	15780-15781	>	_
82-40	15782-15785	4.2	_
82-41	15786-15796	controlled	_
82-42	15797-15800	for	_
82-43	15801-15804	the	_
82-44	15805-15808	FWE	_
82-45	15809-15815	across	_
82-46	15816-15820	both	_
82-47	15821-15827	choice	_
82-48	15828-15836	decision	_
82-49	15837-15840	and	_
82-50	15841-15848	outcome	_
82-51	15849-15850	.	_

Text=For between SCZ-RPS group comparisons, the family-wise error rate was controlled with nonparametric permutation testing (5000 permutations) and threshold free cluster enhancement (TFCE) which effectively controls for multiple comparisons, compared to cluster extent thresholding.
83-1	15851-15854	For	_
83-2	15855-15862	between	_
83-3	15863-15870	SCZ-RPS	_
83-4	15871-15876	group	_
83-5	15877-15888	comparisons	_
83-6	15889-15890	,	_
83-7	15891-15894	the	_
83-8	15895-15906	family-wise	_
83-9	15907-15912	error	_
83-10	15913-15917	rate	_
83-11	15918-15921	was	_
83-12	15922-15932	controlled	_
83-13	15933-15937	with	_
83-14	15938-15951	nonparametric	_
83-15	15952-15963	permutation	_
83-16	15964-15971	testing	_
83-17	15972-15973	(	_
83-18	15974-15978	5000	_
83-19	15979-15991	permutations	_
83-20	15992-15993	)	_
83-21	15994-15997	and	_
83-22	15998-16007	threshold	_
83-23	16008-16012	free	_
83-24	16013-16020	cluster	_
83-25	16021-16032	enhancement	_
83-26	16033-16034	(	_
83-27	16035-16039	TFCE	_
83-28	16040-16041	)	_
83-29	16042-16047	which	_
83-30	16048-16059	effectively	_
83-31	16060-16068	controls	_
83-32	16069-16072	for	_
83-33	16073-16081	multiple	_
83-34	16082-16093	comparisons	_
83-35	16094-16095	,	_
83-36	16096-16104	compared	_
83-37	16105-16107	to	_
83-38	16108-16115	cluster	_
83-39	16116-16122	extent	_
83-40	16123-16135	thresholding	_
83-41	16136-16137	.	_

Text=The SCZ-RPS 2-sample t-tests for the switch> stay and reward> punishment contrast images, were adjusted for confounds (sex, relative, and mean frame wise displacement).
84-1	16138-16141	The	_
84-2	16142-16149	SCZ-RPS	_
84-3	16150-16158	2-sample	_
84-4	16159-16166	t-tests	_
84-5	16167-16170	for	_
84-6	16171-16174	the	_
84-7	16175-16181	switch	_
84-8	16182-16183	>	_
84-9	16184-16188	stay	_
84-10	16189-16192	and	_
84-11	16193-16199	reward	_
84-12	16200-16201	>	_
84-13	16202-16212	punishment	_
84-14	16213-16221	contrast	_
84-15	16222-16228	images	_
84-16	16229-16230	,	_
84-17	16231-16235	were	_
84-18	16236-16244	adjusted	_
84-19	16245-16248	for	_
84-20	16249-16258	confounds	_
84-21	16259-16260	(	_
84-22	16261-16264	sex	_
84-23	16265-16266	,	_
84-24	16267-16275	relative	_
84-25	16276-16277	,	_
84-26	16278-16281	and	_
84-27	16282-16286	mean	_
84-28	16287-16292	frame	_
84-29	16293-16297	wise	_
84-30	16298-16310	displacement	_
84-31	16311-16312	)	_
84-32	16313-16314	.	_

